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CHAPTER ONE 
LITERATURE REVIEW 
Introduction 
Infection with the bacterium Clostridium difficile is a pointed example of the 
costs and benefits of one of the most important tools of modern medicine: 
antimicrobial agents. The first antimicrobial class developed, the penicillins, has a 
broad range of activity against multiple kinds of bacteria, which led to their wide 
usage. But the cost of broad-range activity is collateral damage to the beneficial 
commensal microbiota of the human body, the value of which has only recently been 
appreciated. C. difficile has exploited this feature of modern medicine to become a 
significant pathogen of the human digestive system only in recent times. 
C. difficile is a Gram positive, obligately anaerobic, rod-shaped bacterium of 
the family Clostridiaceae, of the class Clostridia in the phylum Firmicutes. While C. 
difficile (CD) is not part of the normal gut flora of adults, upon antibiotic treatment 
and concomitant reduction of commensal flora, C. difficile efficiently colonizes the 
gut [1, 2]. C. difficile can produce two toxins which damage the colon, causing 
disease ranging from mild diarrhea, to colitis, to fatal multi-organ failure [1, 2].  
Even though the toxins were the earliest identified virulence factor, it has only 
been in recent years that advances have been made in understanding how the toxins 
are regulated, produced, and the mechanism by which they damage the host. Even 
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less is known about other non-toxin virulence factors relating to interactions with the 
host.  
Treatment of CD infection involves further usage of antibiotics, which is 
effective, but also can predispose the gut to the same vulnerable state that precipitated 
the initial C. difficile infection. Re-infection and recurrences are unfortunately 
common [3]. Further compounding this problem is the ability of CD to form a spore, 
a dormant form of the bacterium that is resistant to antibiotics and cleaning agents. 
The ability to persist in the environment has made CD endemic in hospitals and long-
term care facilities. 
Since 2000, rates of CDI have increased, and epidemics of CDI characterized 
by greater incidence, severity and fatality, have been shown to be caused by 
“hypervirulent”  (HV) variants of C. difficile [4-6]. HV epidemics are characterized 
by both increased morbidity and increased environmental predominance and spread.  
Antibiotic usage, virulence factors, and spores have always made CD a 
challenge to control, which has only increased with the emergence of HV strains, 
especially since the virulence mechanisms of HV strains are not well understood. 
These challenges highlight the need to acquire basic information about this pathogen.  
This work seeks to contribute to the greater knowledge about this pathogen, 
by elucidating the phenomena of bacterial adherence, toxin regulation, and spore 
production. Specifically, I have sought to characterize the interaction between 
hypervirulent C. difficile and the epithelia, and one bacterial surface protein that may 
mediate this interaction. I have also sought to clarify other factors that may lead to 
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hypervirulence, by determining the course of toxin production and sporulation over 
the growth cycle of C. difficile. 
Epidemiology of CDI: Causes, Incidence and Control 
Disease Characteristics and History 
The first indication of C. difficile infection (CDI) is usually diarrhea, 
accompanied by fever and bloating if the infection progresses. As the toxins produced 
by CD accumulate in the colon, they continue to damage the colonic mucosa, and 
produce an inflammatory response. A sloughed-off layer of mucous, fibrin, dead 
epithelia and leukocytes, known as a pseudomembrane, forms over the interior 
surface of the colon [7]. More serious sequelae include toxic megacolon, in which the 
colon becomes paralyzed and distended with gas, and carries the possibility of rupture 
[8]. If dehydration is severe, kidney failure can occur. Death can result from any of 
these sequelae if left untreated, and additionally if the toxins become systemic and 
damage the heart [9]. 
The disease and the bacterium were identified separately many years before 
they were linked. Symptoms consistent with pseudomembraneous colitis (PMC) were 
first described in a surgical patient in 1893 [10]. In the early years of penicillin usage, 
researchers noticed that treated animals frequently died of colitis [11, 12]. It was only 
later, with the advent of increased usage of antibiotics in the 1950’s and 60’s, that the 
syndrome of antibiotic-associated diarrhea was observed in humans, although it was 
initially misattributed to Staphlococcus aureus [13, 14]. 
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Historically, before its pathogenic nature was discovered, the bacterium was 
identified in 1935 (known at that time as “Bacillis difficilis”) in one of its more 
benign appearances, in the normal microbiota of asymptomatic infants [15]. C. 
difficile is also frequently found in soil [16] and the gut microbiota of animals [17, 
18]. 
Research to discover the organism responsible for “clindamycin colitis” began 
in the 1970’s. In 1974, Tedesco and colleagues associated the usage of the broad-
spectrum antibiotic clindamycin with pseudomembraneous colitis, one of the more 
serious consequences of CDI, but the agent was till unknown. Toxin of some kind 
was detected in the stools of PMC patients [19], and the infection was thought to be 
bacterial because it responded to vancomycin [20]. Because the toxin was neutralized 
by Clostridium sordelii antitoxin antisera [21], but no C. sordellii could be isolated 
from patients, the search began for other Clostridia in the stools of patients and 
animals with antibiotic-associated disease. In 1978, Bartlett discovered that 
Clostridium difficile was responsible for the disease in humans and animals [22].  
Epidemiology and Antibiotics 
With the widespread usage of myriad antibiotics, C. difficile is now endemic 
in hospitals worldwide. Susceptibility to CDI begins as soon as the microbiota are 
compromised by nearly any antibiotic, and continues until the biota recover and 
return in quantity sufficient to exclude CD, which can be a significant time after the 
course of treatment ends. Some antibiotics evidence higher relative risk for CDI than 
others, such as ampicillin (or amoxycillin) and cephalosporins [23-25]. Third-
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generation cephalosporins remain widely prescribed and show high relative risk for 
CDI [26, 27], particularly because CD is naturally resistant to this class.  
If CD is resistant to the antibiotic, then it will be able to colonize during the 
course of treatment, in addition to after treatment. This longer window of 
susceptibility favors resistant strains, and as would be expected with selection 
pressures, the most prevalent epidemic CD strains are often resistant to the antibiotics 
in common use [28]. For example, as mentioned earlier, in the 1970’s rates were 
highest for clindamycin, and many epidemics throughout the 1980’s and 1990’s were 
caused by clindamycin resistant strains [29]. These strains contained the erm gene, 
which confers resistance to macrolides, lincosamides and streptogramins [29, 30]. 
Recent epidemics have been characterized by recently evolved resistance to the 
fluoroquinolone class of antibiotics, which are currently in wide use [6, 28]. 
Fortunately, resistance to the two antibiotics primarily used to treat CDI, 
vancomycin and metronizadole, has not emerged, although increases in the amount of 
metronidazole required to treat CDI have been observed. [31]. However, in the search 
for additional treatment options, other drugs that have been used, such as rifaxamin, 
and have become resistant rapidly [32]. For a review of the clinical treatment of CDI, 
including recent challenges, the reader is referred to the review by Kelly and Lamont 
in the NEJM [33]. 
CD is one of the most commonly isolated cause of nosocomial diarrhea [34, 
35], but estimates of how many patients become colonized with CD, and the 
proportion that become ill has varied widely from the time the organism was 
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described. Before the disease was recognized, and control measures implemented, 
rates of diarrhea were as high as 20% for those treated with clindamycin, with a 10% 
rate of PMC. [36]. Colonization rates in the general population are estimated to be 
around 2-3% [37, 38]. Current data estimates that 15-25% of nosocomial diarrhea 
cases are due to CD [8]. Several carefully controlled studies determined that about 
20% of patients acquired CD during their hospital stay, and that most of those remain 
asymptomatic. [39-41].  
One general trend is that all rates are unfortunately increasing. 
Epidemiological data from the UK indicated that the number of deaths reported with 
CD as a cause or contributor has grown approximately 8-fold from 1999 to 2007, and 
that CD was responsible for more deaths than Methicillin-Resistant Staphlococcus 
aureus (MRSA) [42]. In the USA, in the late 1990’s, one measure of yearly CDI 
cases numbered 82,000, but rates in the mid 2000’s had doubled[43]. Mortality rates 
in the US between 1999 and 2004 have increased 35% per year [44]. These increases 
are primarily attributed to the emergence of more virulent strains of CD, which will 
be discussed in detail later in this work. 
Risk Factors for CDI 
Factors that increase a person’s risk of contracting CDI include both intrinsic 
characteristics and medical manipulations. Antibiotic use evidences the highest risk, 
with a relative risk of 5.9 for diarrhea and 4.2 for asymptomatic carriage [25]. In 
addition to exposure to precipitating antibiotics, hospitalization places a vulnerable 
patient in an environment frequently contaminated with CD spores. Factors related to 
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hospitalization, such as length of stay, severity of co-morbid conditions, and 
proximity to a contaminated environment also increase relative risk [25, 45]. 
Advanced age is correlated with increasing propensity for CDI [46-48], mainly due to 
these patients having more severe co-morbidities [5, 49] and possible immune 
senescence, but not necessarily greater exposure to antimicrobials [50].  
Exposure to antacid medication has been a risk factor of recent debate. The 
data have been contradictory, with some studies indicating increased risk CDI [51, 
52], while other studies finding no association [28, 53, 54], more recent data have 
accumulated indicating that antacid medication does increase risk, and that the risk is 
proportionate to the degree of acid suppression [55]. Because CD spores, the assumed 
infectious particles, are naturally resistant to acid, the mechanism of this effect 
remains unknown, although it is proposed that vegetative cells may be the infectious 
agent in these cases [56]. 
Immunity and Vaccines 
The patient’s immune response is one characteristic that is predictive of a positive or 
negative outcome. People who have an existing response in the form of IgG to Toxin 
A were significantly less likely to develop symptomatic disease [57]. Because of this 
association of Toxin A antibodies and disease in human populations, most vaccine 
efforts have focused on the toxins. 
Early work with Toxin A in animals showed that toxoid vaccines elicited 
immunity [58, 59]. In humans, A toxoid vaccine was shown to elicit IgG against toxin 
A levels that exceeded those shown protective in the survey of symptomatic and 
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asymptomatic patients [60], and is also effective in recurrent cases [61]. A DNA 
vaccine, in which a gene for the receptor binding region of Toxin A was injected into 
mice, also produced high titer antibodies [62]. 
Adhesins and other surface proteins are also attractive vaccine candidates, 
such as the surface proteins in the MeNZB meningococcal vaccine [63]. CDI patients 
develop antibodies to surface proteins following infection [64]. As with the toxins, it 
has been noted that patients with lower levels of antibodies to CD surface proteins 
were more likely to have relapses of CDI [65]. In animal models, while passive 
immunization with antibodies to the surface layer protein SlpA prolonged life, a 
vaccine against SlpA was not been able to elicit protective immunity [66]. However, 
vaccines with total cell wall extracts have shown some effect [67]. 
Economic models of a C difficile vaccine have shown that it would be cost 
effective to treat both patients at risk for CDI and those who already have contracted 
the disease to prevent recurrence [68]. 
Costs and Prevention 
As mentioned earlier, rates are increasing across the board, as evidenced by 
increasing rates of infection previously low-risk populations, such as children and 
pregnant and peripartum women [69-71].  
Clinically, the cost of C. difficile infection (CDI) is great. Nosocomial C. 
difficile infections prolong hospital stays and increase costs. One recent meta analysis 
estimated that each case of CDI adds approximately US$3000 to $4000 to patient’s 
hospital bill in the USA ($8500 outside the USA), and recurrent CDI can add up to 
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$18,000 [72]. In 2002, Kyne et al used costs per patient described in prospective 
study to project the total cost of CDI to the US healthcare system, which was $1.1 
billion [73]. With the increase in rates due to recent epidemics, costs are now 
estimated to be $3.2 billion per year for the United States [74].  
To acquire C. difficile, a susceptible patient must ingest C. difficile spores 
from the environment. In the hospital, spores are found on surfaces, medical devices 
and can be transferred to patients by transient hand carriage by healthcare personnel 
[2]. CD spores are not killed by alcohol-based hand gels [75], and the recent rise in 
CDI rates has been partially attributed to the increased usage of these gels in lieu of 
traditional soap and water hand washing [76]. Unfortunately, exposure to some 
detergents only increases sporulation rates of vegetative CD [77]. Sodium 
hypochlorite is one agent consistently effective against spores [77, 78]. Rates of 
transmission have been reduced by encouraging proper hand washing and glove use, 
employing disposable medical equipment, and using bleach to clean surfaces [79-81].  
An effective strategy for CDI prevention has been to limit the usage of 
precipitating antibiotics. For example, usage of the antibiotic clindamycin was 
restricted due to its association with CDI, and outbreaks of resistant strains have been 
controlled by limiting its usage [82]. Cepahlosporin usage has also followed a similar 
pattern [83]. During the outbreak of hypervirulent CD in Québec in the mid-2000’s, 
limiting the use of cephalosporins, ciprofloxacin, clindamycin and macrolides 
reduced CDI cases by 60% [84]. The most successful approach for reducing 
epidemics has been to implement infection control at multiple levels, including 
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increased cleaning measures and hygiene, antibiotic stewardship, and increased 
patient monitoring. This “bundle” approach has been effective at reducing CDI rates 
by as much as 78% [85]. 
 
Pathogenesis 
 Toxins 
Even when CD was first described in healthy infants, it was noted that culture 
filtrate of the organism could kill rabbits when injected [15]. We now know that 
disease-causing CD produce at least two toxins. When CDI was first being described, 
the two toxins were described independently, and initially confused [86]. At the time, 
there was controversy about the contribution of each toxin in the disease process, 
which interestingly, has been revisited recently.  
Toxin in the stools of PMC patients was cytotoxic to mammalian cells in 
culture [19], and supernatants of CD were able to produce PMC lesions in animals 
[87]. In 1981, two independent research groups used ion exchange chromatography to 
separate secreted proteins, and showed that there was another large toxin present, 
which was called Toxin A [88, 89]. Toxin A produced less rounding of fibroblasts in 
culture, but was able to produce fluid accumulation in ligated ileal loops of rabbits, 
while Toxin B could not. Also, the work of Lyerly and Wilkins in 1985 showed that 
when given intragastrically, Toxin A produced a similar profile as total supernatant, 
which Toxin B did not, unless mixed with small amounts of Toxin A, or given to 
animals with bruised ceca [90] . It was concluded that Toxin A was the chief 
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virulence factor, and Toxin B, while a potent cytotoxin in culture, required Toxin A 
to be present, to begin the cascade of damage to the colonic mucosa and produce 
disease at the organismal level [86]. 
Before the development of genetic tools to manipulate CD, natural mutations 
and variations in the toxin genes were sought out to shed some light on their function 
and role in pathogenesis, especially in the debate as to which toxin was most 
important. Clinical reports surfaced of variant CD strains that were causing disease, 
but produced no detectable Toxin A. This challenged current thinking, and was not 
only academically interesting, but it also had ramifications for the clinical practice. At 
that time, clinical immunoassays only tested for the presence of Toxin A. The first 
Toxin A-negative Toxin B positive (A-/B+) strain described was strain 8864, 
described by Lyerly et al in 1992 [91], which/who demonstrated that in produce no 
Toxin A in vitro by immunoassay, and that Toxin B from 8864 was more lethal and 
weakly enterotoxic to animals. Strain 8864 was later shown to have a deletion 
encompassing the 3’ends of tcdA and tcdC and that the Toxin A protein lacks the 
receptor binding repeats and translocation domain [92] While strain 8864 had an 
obscure clinical origin, other disease-causing A-B+ strains were being reported more 
frequently in the early 1990’s. Strain 1470 and related isolates [93, 94] also have 
deletions in tcdA and were negative in clinical tests for Toxin A, were initially 
thought to be non-pathogenic in mice [93], but further work in the more sensitive 
hamster model [95] and fatal cases in humans [96] and human epidemics soon 
dismissed this idea [97-100]. However, Toxin B from these strains shared homology 
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with a toxin from a related Clostridium species, TcsL from C. sordelii [101], in its 
enzymatic domain, which allows it a larger range of host molecule specificity and 
increased toxicity. This variation in Toxin B’s enzymatic domain left the debate 
concerning Toxin A vs. B open. 
Recent advances in the genetic manipulation of CD have finally allowed a 
molecular scientific answer to this question. Using an unstable plasmid as a 
recombination vector [102], Julian Rood’s research group were able to construct 
isogenic mutants in the genes for Toxin A and Toxin B in strain 630 [103]. When 
these mutant strains were introduced into the hamster model, it was shown that Toxin 
B was the required virulence factor. Hamsters infected with the Toxin A mutants CD 
showed no difference in mortality as compared to wild-type. In contrast, the group of 
hamsters infected with the Toxin B mutant CD showed significantly less mortality, 
and analysis of the CD obtained from the fatal cases indicated that they were revertant 
strains in which recombination vector was excised, also supporting the idea that 
Toxin B production is favored for pathogenesis and survival in the gut [103].  
However, a more recent study has found conflicting results. Using the 
ClosTron sytem of a re-targetable group II intron [104], null mutations were made in 
tcdA and tcdB [105]. In contrast to the previous study, both toxins contributed to 
virulence in the hamster model. However, hamsters infected with CD lacking Toxin B 
survived for several days longer than those infected with CD lacking Toxin A [105]. 
While both may participate in the disease process, it appears that Toxin B makes the 
larger contribution to virulence  
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The Structure and Regulation of the Pathogenicity Locus 
Early research also recognized that there were strains of CD that did not cause 
disease or produce toxins in culture. The mechanism behind these non-toxigenic 
strains was not known, but it was suspected that they lacked the genes for the toxins, 
which was confirmed when the toxin genes were sequenced, and later when the whole 
genetic island on which they reside was described. The individual genes for Toxin 
And Toxin B were sequenced in 1990 [106, 107], and the neighboring genes were 
later sequenced and designated the Pathogenicity Locus or PaLoc by Eichel Streiber’s 
group in 1996 [108]. Non-toxigenic strains of C. difficile that lack this genetic locus 
entirely, having only a 115 bp “scar” in the same region [109].  
The genes for toxins A and B, tcdA and tcdB (formerly toxA and toxB), are 
located in the PaLoc with three other genes, tcdR, tcdE and tcdC (Figure 1A) [108]. 
The toxin proteins are among the largest bacterial toxins described, and are encoded 
by single genes. In strain VPI 10463, tcdA is an 8133 bp gene which codes for a 2710 
amino acid, 308 kD protein, while tcdB is 7098 nucleotides, which codes for a TcdB 
molecule of 2366 amino acids and 279kD [106, 107]. 
Toxin B and Toxin A are 44.8% identical and 63.1% similar at the amino acid 
level, and may have originated from a gene duplication event [110]. Both share 
similar overall topology, with an N-terminal enzymatic domain, a central putative 
translocation domain, and a C-terminal receptor-binding domain consisting of 
multiple repeats (Figure 1B). Briefly, the enzymatic domain modifies host signaling 
proteins, the translocation domain may be involved in the transit of the toxin through 
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host membranes, and the receptor binding domain is responsible for the binding of 
toxin to sugar moieties on the host cell surface. TcdA and TcdB are most similar 
(74% homologous) in the N-terminal enzymatic domain [111], which confers 
substrate specificity. The two CD toxins belong to a superfamily of similar molecules 
known as the Large Clostridial Toxins, which also includes the lethal and 
hemorrhagic toxins of C. sordellii, and C. novyii alpha toxin [112], all with similar 3-
domain structures and mechanisms of action. 
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Figure 1. A. Schematic of the Pathogenicity Locus. Arrows indicate the direction 
of transcription. B. Structure of Toxins A and B. Adapted from Jank et al, 2007 
Glycobiology 14(4) 15R-22R. 
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In addition to the toxins, the locus encodes for three other genes, tcdR, tcdE 
and tcdC (Figure1A). tcdR (formerly tcdD or txeR) codes for a alternate sigma factor 
required for the expression of tcdA and tcdB [113]. TcdR is a 22kD protein that 
features a helix-turn-helix DNA binding motif [114], and has defined a new group of 
the sigma 70 family of sigma factors, Group 5 or Extra-Cytoplasmic Function (ECF) 
[115, 116]. As a sigma factor, it binds to RNA polymerase, and allows transcription at 
specific promoters. Mani and Dupuy first demonstrated that TcdR was required for 
tcdA and tcdB expression in vivo and could activate toxin promoter-specific 
transcription in vitro [113]. TcdR is also homologous to toxin-inducing regulators for 
other Clostridia, such as BotR of C. botulinum and UviA of C. perfringens, and can 
substitute for UviA in in vivo transcriptional studies [115, 117-119].  
tcdE encodes a protein of unknown function with homology to phage holins. 
Because the toxins do not have classical secretion signals, TcdE has been implicated 
in toxin release during stationary phase [120]. When expressed in E. coli, tcdE 
produces membrane lysis as visualized by microscopy [120]. Along these same lines, 
infection of CD with lysogenic phages has been shown to increase release of toxins, 
although not transcription of toxin genes, presumably by providing additional holins 
[121]. 
tcdC is transcribed on the opposite strand from the other PaLoc genes, and is 
postulated to act as negative regulator [122]. This unique 26 kDa protein has no 
homology to any described regulatory protein [122], and it is membrane-associated 
[123]. The function of TcdC in the regulation of toxin production is the center of 
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much recent debate. The earliest data regarding the function of TcdC was a 
transcriptional study by Hundsberger et al [119]. Using semi-quantitative RT-PCR, 
they noted that transcription of tcdA, tcdB, tcdR and tcdE was not detectable during 
exponential growth, but increased as bacteria entered stationary phase. However, 
tcdC transcripts evidenced the opposite pattern, being transcribed in exponential 
phase, and declining in stationary phase.  
This pattern of transcription led to the hypothesis that TcdC was acting as a 
negative regulator in exponential phase, the mechanism was unknown. The first 
functional studies of TcdC demonstrated that, in a heterologous system, TcdC 
strongly decreased the TcdR-dependent transcription of tcdA promoter linked to a 
reporter gene. Gel shift and surface plasmon resonance assays indicated that TcdC 
appears to act as a novel kind of anti-sigma factor by inhibiting TcdR from 
complexing with RNA polymerase core enzyme, or preventing the holoenzyme from 
forming an open complex [122]. 
These data, and data concerning the function of TcdR as a positive regulator 
have led to the current model of PaLoc regulation (Figure 2) [124]. In general, Toxins 
A and B are produced in stationary phase in response to starvation. When nutrients 
are abundant, expression of the toxin genes is repressed by the global stationary-
phase regulator CodY, which binds to a region upstream of tcdR and prevents its 
transcription. Without TcdR to act as a required sigma factor, transcription of tcdB 
and tcdA is not possible (Figure 2A) [119, 122, 125]. In a C. difficile CodY mutant, 
toxin production was de-repressed and toxin production occurred during exponential 
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phase [125]. During stationary phase, lower levels of particular nutrients decrease the 
binding affinity of CodY for its target sequence, allowing for read-through 
transcription of tcdR. tcdR is transcribed, and then goes on in a positive feedback loop 
to promote its own transcription as well as that of tcdB, tcdE and tcdA (Figure 2B). 
Transcription is primarily monocistronic, initiated from individual promoters 
preceding tcdB and tcdA, but polycistronic read-through transcripts do originate from 
upstream promoters as well [119, 126, 127]. 
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Figure 2 Model for the regulation of the Pathogenicity Locus of Clostridium 
difficile. A. Exponential Phase. B. Stationary Phase. Adapted form O’Connor et 
al, 2008, Gastroenterology 136(6), 1913-24. 
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Nutritional effects on toxin production are myriad and complex. It had long 
been reported that toxin production was catabolite repressed [126, 128]. Catabolite 
control appears to be exerted through CodY, although not directly. The presence of 
branched-chain amino acids (isoleucine and valine) and GTP increase the binding 
affinity of CodY to the DNA [125, 129]. Glucose exerts its effect indirectly through 
the TCA cycle by influencing the fermentation of amino acids [128]. Biotin is 
essential for growth, but may repress toxin production [128, 130], as may certain 
amino acids such as lysine and cysteine [131].  
Mechanism of Toxin Action and Host Responses 
In defining the mechanism of the CD toxins, some information is relevant to 
only one toxin or another, but chiefly evidence has accumulated that demonstrates 
that they function similarly, with particular limitations noted. Following secretion, the 
first step in intoxication is binding to the host cell surface. In this case, more is known 
about Toxin A than Toxin B. The C-terminal CROP region has homology to a glucan 
binding protein from Streptococcus mutans [110, 132]. Toxin A can bind to several 
types of carbohydrate moieties, which vary by cell, tissue and species. For example, 
Toxin A binds to and agglutinates rabbit erythrocytes, but the carbohydrates on the 
surface are not found in other mammalian erythrocytes [133, 134]. In 1991, Tucker 
showed that toxins bound to human carbohydrate antigens I, X and Y- all of which 
contain the core Galbeta1-4GlcNAc, although some doubt has been raised about this 
result [135]. Recent crystal structures have indicated that Toxin A binds to two 
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carbohydrate molecules (in this case, alpha-Gal-(1,3)-beta-Gal-(1,4)-beta-GlcNAc 
O(CH(2))(8)CO(2)CH(3))in each of seven conserved binding pockets in the CROP 
region (Figure 3A) [136]. On the surface of epithelia, this moiety could be attached to 
a glycoproteins or glycolipids. Recent data suggest that a glycoprotein on human 
cells, gp96, binds to Toxin A [137]. The varieties of carbohydrate modifications on 
human gut epithelia are one proposed explanation for why animal and human 
newborns do not become ill when colonized with CD, as these structures change over 
development [138]. 
The receptor for Toxin B is unknown, but in vitro tests indicate that it is 
distributed differently than the receptor for Toxin A. Toxin A can bind to both the 
apical and basal side of polarized T84 cells in culture, and decrease trans-epithelial 
resistance, but Toxin B could only do so from the basal side, or with small amounts of 
A from the apical side, once again pointing to some synergy between the two toxins 
[139]. 
Once bound, the toxins are endocytosed via a clathrin-mediated endocytosis in 
a dynamin-dependent manner [140, 141]. Early work by [142] indicated that 
acidification was required for Toxin A to become active in vivo. The cytotoxicity of 
Toxin B was also shown be abrogated in the presence of bafilomycin, which blocks 
the acidification of endosomes [143, 144]. Fractionation studies indicated that the 
enzymatic fragment is delivered into the cytoplasm, while the translocation domains 
and CROP regions remain in the endosome [145]. The acidification allows the 
membrane translocation region to change conformation and insert into the membrane 
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of the early endosome [144]. If the hydrophobic translocation domain is deleted, the 
cytotoxicity of Toxin B is reduced by more than 90% [146]. The pore-forming 
process for both Toxins requires cholesterol-containing membranes [147]. 
Recent work has defined how the enzymatic domain enters the cytosol. Early 
work suggested that the toxins required proteolytic cleavage to become active, as 
protease inhibitors could blunt the action of Toxin A on cells [148]. Recently, it has 
been discovered that a host co-factor, inositol hexakisphosphate, induces autocatalytic 
cleavage and activation of C. difficile toxin B in the cytoplasm [149]. The auto 
catalytic cleavage was initially thought to be a serine protease located C-terminal to 
the hydrophobic domain [149], but later work determined that the autocatalytic 
domain was a cysteine protease domain located closer to the enzymatic domain 
(Figure 3B) [150]. 
23 
 
 
Figure 3. A. Structure of Toxins. Adapted from Jank et al, 2007 Glycobiology 
14(4) 15R-22R. B. Toxin B domains, adapted from Egerer et al, 2007 J Biol 
Chem, 282(35) 25314-21. 
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Once the enzymatic domain enters the cytosol, it exerts its effect on the small 
GTP binding proteins of the Rho and Ras superfamilies, particularly Rho, Rac, Ras, 
and Cdc42 [151]. Small GTPases are signaling proteins that cycle between an active, 
GTP-bound state and an inactive, GDP-bound form. Guanidine exchange factors, or 
GEF’s receive activation signals and exchange GDP for GTP.  In this form, they can 
interact with a variety of effectors. The active state ceases with GTP hydrolysis to 
GDP, aided by GTPase activating proteins (GAP’s) [152].  
Toxins A and B perturb this process by glucosylating the small GTPases, 
which permanently fixes them in the inactive form by the transfer of the glucose 
moiety of UDP-glucose to a threonine residue in the switch region of the GTPases 
[153, 154]. In the enzymatic domain of the toxins, the DXD motif is essential; 
mutating it leads to a loss of enzyme activity [155]. This motif is thought to mediate 
nucleotide-sugar binding in the presence of a Mn2+ ion [155], [156]. This 
glucosylation blocks the cycling of the GTPases between the membrane and the 
cytosol, parking them inactive at the membrane [157]. It also blocks the action of 
GEFs and GAPs, so no new GTP can be exchanged, and most importantly, it blocks 
the interaction with effectors [158, 159], the chief effect of this irreversible 
glucosylation is significant effects on the host cell cytoskeleton. Rho family members 
are in particular involved in the regulation of the actin cytoskeleton, the disruption of 
which is responsible for the cell rounding and neurite formation seen in intoxicated 
cells in culture [151]. Another downstream effect of inactivated GTPases is the 
induction of apoptosis via Caspase 3, 6, 9 and Bid [160].  
25 
 
 
The toxins also have effects independent of GTPase activity, for example, 
they cause mitochondrial damage [161], which also induces apoptosis. In 
macrophages, Toxins A and B activate the inflammasome, induce the release of Il-
1B, and start the cascade of an inflammatory immune response [162]. 
The consequences of this intoxication on gut epithelia are disruption of tight 
junctions [163, 164]. Toxins also have systemic effects, which may be responsible for 
death due to CDI. In a study using zebrafish embryos as a model system, Hamm et al 
demonstrated that Toxin B localizes to the heart, decreases contractility and induces 
apoptosis in heart tissue [9]. 
 Binary Toxin and other virulence factors 
In 1997, a new C. difficile toxin was discovered [165]. Similar to binary toxins 
found in other Clostridia, such as iota toxin of C. perfringens, it has a structure 
consisting of two separate components, which combine to make the fully functional 
toxin [165]. Each component is encoded by one of two two neighboring genes. Most 
described Clostridial binary toxins are believed to function by the same mechanism 
[166]. In CD, CdtA is the enzymatic component, and CdtB is the binding and 
translocation component. The two fragments are secreted separately, and combine in 
the external millieu for the fully functional toxin. The binary toxin is taken up by 
receptor mediated endocytosis, and the acid environment induces pore formation and 
the translocation of the enzymatic component [166]. Once inside, they ADP-
ribosylate actin, which leads to the disintegration of the cytoskeleton. Expression of 
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cdtAB genes is regulated by a third member of the CDT locus, the orphan response 
regulator CdtR [167]. 
Surveys indicate that a minor percentage of C. difficile strains carry the binary 
toxin Locus, with estimates ranging from 5.8 to 15.5 % [168-170] It is distinct from 
the PaLoc, and has been found in strains which do not carry the PaLoc [169]. In 
animal models its function remains obscure. Strains that produce binary toxin but not 
the LCT’s are able to colonize animals, but produce no diarrhea or disease. However, 
purified toxin can cause fluid accumulation in the ligated ileal loop assay [171]. Its 
contribution to CDI, whether alone or in combination with the LCT’s in humans is 
still under investigation. 
C. difficile produces other non-toxin virlence factors such as several 
hydrolytic enzymes, fimbriae and a capsule [172]. The hydrolytic enzymes includes 
hyaluronidase, collagenase, and a chondroitin-4-sulfatase, which are predicted to act 
to release nutrients in the gut [173]. While unrelated to the production of toxin, the 
presence of these enzymes was more frequent in highly toxigenic strains [174].  
Sporulation  
CD spores are metabolically inactive forms of the bacteria that terminally 
differentiate from vegetative cells. Spores are resistant to heat, desiccation, and 
chemical onslaughts. Spores can persist in aerobic environments, such as on surfaces 
in hospitals. Because of these features, and because they are resistant to destruction 
by stomach acid, spores are the infectious particle leading to CDI. Thus, their 
development and function are highly relevant to CD pathogenesis. 
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The production of spores begins when the vegetative cell undergoes a special 
kind of cell division in which the cell is divided into two unequal compartments. The 
larger compartment is called the mother cell and the smaller is the forespore. The 
forespore becomes enveloped by and develops inside the mother cell. The mother cell 
lyses to release the spore. Sporulation is a complex process of seven stages of 
development (Figure 4). First, the nuclear material is replicated and forms an axial 
filament. Instead of a central septum forming as in normal cell division, an 
asymmetrical invagination of the membrane pinches one copy of the chromosome 
with the developing forespore septum, in stage II. The remaining portion of the 
chromosome is actively transported into the forespore that is then sealed by the 
completion of the septum. In stage III, the membrane of the mother cell grows and 
engulfs the forespore forming a vesicle with two membranes. During stage IV, a 
cortex of peptidoglycan forms between the two cells, and calcium and diplocolinic 
acid accumulates in the forespore. Next, a thick proteinaceous coat comprised of 
multiple proteins is assembled on the outer forespore membrane in stage V. The spore 
matures in stage VI, with the completion of coat synthesis, accompanied by an 
increase in refactility upon the dehydration of the forespore. In the final step, the 
mother cell lyses by the action of lytic enzymes and the mature spore is released. 
[175]. 
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Figure 4. Stages of Sporulation as described in Bacillus subtilis. Figure courtesy of 
Timothy Paustian, University of Wisconsin-Madison. 
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This complex developmental program is the result of stepwise gene 
expression, controlled by a cascade of sigma factors. In general, sporulation is 
induced by starvation, and additionally for C. difficile by the presence of oxygen. In 
the better-described system of Bacillus subtilis, nutrient deprivation stimulates a 
phospho-relay resulting in the phosphorylation of the master regulator, Spo0A. C. 
difficile does not have a multicomponent phosphorelay [176], but one orphan sensor 
kinase has recently been identified, and was able to phosphorylate CD Spo0A [177]. 
A mutant in this gene was compromised for sporulation [178]. 
Once active, Spo0A activates downstream regulators involved in sporulation, 
and represses other regulators involved in vegetative functions. The chief controllers 
of sporulation are two cascades of sigma factors, one that is active in the spore, 
consisting of Sigma F and Sigma G, and one that is active in the mother cell, 
consisting of Sigma E and Sigma K [175]. These sigma factors are synthesized in an 
inactive form and activated by specific sequential signal. Spo0A, along with 
housekeeping and stationary phase regulators, initiates the formation of the septum. 
Once the compartments are divided, the inhibitors of Sigma F are deactivated in the 
forespore and Sigma F is activated. Sigma E in the mother cell is activated by 
proteolytic cleavage. Sigma E directs the production of coat proteins, and by 
communication with the forespore (by an unknown mechanism) activates Sigma G. 
Sigma G directs the production of a signaling and proteolytic cascade that results in 
the activation of sigma K, the final sigma factor. Sigma K directs the assembly of the 
outer layer of the spore [175]. 
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Interestingly, in both B. subtilis and CD, the Sigma K gene is interrupted by a 
pro-phage element, although not the same one. While disposable in B. subtilis, the 
excision of this element during sporulation is required for proper timing of the 
activation of Sigma K in C. difficile [179]. CD lacks a homologue of the protease that 
activates Sigma K, and CD Sigma K lacks the signal sequence for cleavage, so the 
excision of this element is the main regulator of the activity of Sigma K. Premature 
activity of Sigma K results in a 100-fold decrease in sporulation efficiency in a CD 
strain without the prophage element [179]. Variations in sporulation efficiency in 
different strains or populations could conceivably affect the spread of CD in the 
nosocomial environment.  
Germination is an equally complex process, and is key to the initiation of 
disease. Again, not much is known about CD germination. In B. subtilis, germination 
begins when germinants such as glucose, peptidoglycan, or calcium are sensed by 
receptors in the inner membrane of the spore. After receptor binding, an irreversible 
program begins in which divalent cations and calcium-dipicolinic acid are released, 
leading to an influx of water, which results in an expansion of the core [180]. Finally, 
the hydrolysis of the cortex peptidoglycan is followed by active metabolism and 
outgrowth [180].  
While B. subtilis spores germinate in response to nutrients such as glucose, 
CD must sense several features characteristic of its appropriate niche in the human 
gut. No homologues exist in the CD genome to the B. subtilis germinant receptors 
GerA, B and K [181, 182].  However, it has long been noted that adding a primary 
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bile acid, taurocholate, to culture media improves spore recovery [183-185]. 
Taurocholate and glycine are abundant in bile, and have been demonstrated to 
activate germination [181]. The receptors for taurocholate and glycine are unknown, 
but kinetic data suggest a sequential progression of binding of taurocholate followed 
by glycine to specific receptors [186]. 
The interaction of taurocholate and the microbiota may underlie how CD is 
normally excluded from the human gut. While taurocholate is a CD germinant, it is 
hydrolyzed in the gut by other bacteria to secondary bile salts such as cholate and 
chenodeoxycholate. These derivatives, chenodeoxycholate and deoxycholate, inhibit 
germination and vegetative outgrowth [187]. In vivo, antibiotic-treated mice have a 
higher proportion of primary to secondary bile salts in their ceca, and cecal contents 
better promote the growth of CD ex vivo [188]. This may explain the mechanism by 
which antibiotic treatment predisposes patients to CDI. 
The Emergence of Hypervirulent Strains 
As mentioned in the Epidemiology section, in the past ten years epidemics of 
CDI characterized by greater incidence, severity and fatality have been shown to be 
caused by highly virulent variants of toxigenic C. difficile [4-6]. Past epidemics were 
usually confined to a particular institution, although occasionally there have been 
epidemics of a particular strain over a wider geographic area, such as the J9 strain 
outbreak in the eastern US in the 1990’s [189].  
Three major outbreaks in the early 2000’s were indicators of an 
unprecedented larger problem. In 2000, a cluster of severe cases of CDI occurred at 
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the University of Pittsburgh Medical Center. Incidence of CDI roughly doubled in 
one year, with a sharp increase in mortality and morbidity, including nine patients 
requiring surgery to remove their permanently damaged colons [190]. The next major 
outbreak was in Montreal, Canada during 2003, where CDI incidence quadrupled as 
compared to previous years, and CD caused or contributed to 244 deaths [5]. 
Increased morbidity was also seen, with 33 patients requiring colectomies [5].  The 
highest rate of mortality (approximately 11% of CDI cases) occurred during two 
outbreaks between 2003 and 2005 at the Stoke-Mandeville hospital the UK in which 
38 people died [191].  
As outbreaks accumulated, genetic typing studies indicated that these 
outbreaks were caused by a single genetic cluster of C. difficile [6]. Hypervirulent 
strains cluster into a distinct genetic group by several different typing methods: Multi-
Locus Sequence Typing [192], toxinotyping [193, 194] where they are designated 
type III, PFGE and PCR ribotyping [194] where they are designated type NAP1/027, 
and Restriction Endonuclease Analysis [6] where they are called group BI. After this 
identification enabled tracking, BI strains have been found responsible for CDI 
epidemics worldwide [6, 195-199]. A large study using comparative phylogenomics 
has shown that there are four distinct clades of C. difficile, and that the HV strains 
comprise their own clade, HY, as shown in Figure 5 [200].  Toxigenic strains 
comprise the HA1 clade. Non-toxigenic strains and Toxin-variant strains comprise a 
third clade, A-B+, and animal derived isolates form the HA2 clade. 
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Figure 5 Phylogenetic relationships of Clostridium difficile strains as determined by 
microarray analyses. Strains distributed into four major clades (HY, A-B+, HA1, and 
HA2). Strain names are shown at the end of the branches and are colored according to 
the animal source of isolation. Black, human; blue, mouse; green, bovine; red, swine; 
light blue, equine. Branches with ** have a P value of 1.0 and represent 100% of all 
phylogenies showing a given topology. * indicates a P value of ≥0.98. Figure from 
Stabler et al, J Bacteriol. 2006.  
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To understand the virulence mechanisms of HV strains, initial work focused 
on known virulence factors, namely antibiotic resistance and toxins. As mentioned 
earlier, strains of CD resistant to the antibiotics in common usage have a competitive 
advantage. Fluoroquinolone usage has been a significant risk factor in HV epidemics 
[28]. The HV strains are resistant to the fluoroquinolone class of antibiotics, and 
particularly to gatifloxacin and moxifloxacin, which have the strongest anti-anaerobe 
activity [6]. Resistance arises from a single amino acid substitution in the target of 
fluroquinolones, DNA gyrase [201]. This resistance appears to be recently evolved, as 
historical CD clinical isolates of the BI genetic group are not fluoroquinolone 
resistant [6, 75].  
Because of the severity of disease seen in the early epidemics, toxin 
production was a target of initial investigations. HV CD is toxinotype III and 
produces both toxins, and also Binary Toxin [5]. As mentioned earlier, the 
contribution to Binary Toxin to human disease is unknown. Sequencing the tcdB from 
HV strains has shown that the enzymatic domain is only about 90% identical as 
compared to the sequenced strain 630 [200, 202]. This altered enzymatic domain may 
have different activity against the GTPases. The C-terminal binding domain is also 
different, which may affect the cell type tropism of HVCD. In vitro, purified TcdB 
from an HV strain displayed increased cytotoxicity across a broader range of cell 
types than non-HV strains, however the mechanism for this difference is not yet 
known [202].  
The majority of the research into HV toxins has focused on the relative 
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amounts of the two toxins produced. These values, and their potential impact on 
disease severity are the subject of debate [203, 204]. In 2005, a study by Warny et al 
found that the median amounts of toxins A and B in a group of HV strains were 16 
and 23 fold higher, respectively, than the median toxin amounts for a group of non-
HV strains, and concluded that HV strains also expressed toxins during exponential 
growth, although no quantitative toxin measurements were presented for the 0-24 
hour time period [194]. On the other hand, in 2006, Akerlund et al found that one HV 
strain produced 3-13 fold more toxin that a group of non-HV strains. In 2007, using a 
human gut model, Freeman et al [205] reported that while mean toxin titers were not 
significantly higher for an HV strain than for a non-HV strain, the HV strain had an 
extended duration of toxin production. The fold differences espoused by Warny et al 
have been most frequently cited, in scientific journals and popular media [206, 207] 
,[208, 209]. 
While the toxin genes in HV strains were intact, initial analysis of the PaLoc 
found that tcdC from HV strains contains an 18bp deletion as compared to published 
sequences. This variation in this negative regulator was initially suspected to be 
responsible for the HV toxin phenotype [5]. Further sequencing of tcdC identified a 
single base pair deletion at position 117 that produces a frameshift mutation, 
rendering the protein truncated and likely non-functional [122, 194, 208]. 
Biochemical studies demonstrated that the 18bp variation had no effect on TcdC 
function [122]. Clinical studies also showed no correlation with disease severity with 
the 18bp deletion, which has also been found in non-HV strains [210]. 
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While the tcdC truncation has been well described in HV strains, its direct 
contribution hypervirulence is unknown. Whether the lack of this negative regulator 
is sufficient to account for toxin production during exponential growth, as proposed 
by Warny et al [194], has not been specifically tested.  
Although an increase in toxin production may account in part for increased 
disease severity, it does not fully explain why hypervirulent strains also predominate 
in the hospital environment during and after an epidemic [197], or the rapid 
geographic spread of hypervirulent C. difficile.  As mentioned earlier, the most likely 
form of C. difficile in the healthcare environment is the highly resistant bacterial 
spore, which is spread to susceptible patients either by environmental contact or 
carriage by healthcare personnel [211, 212]. A study by Akerlund et al showed that 
one strain of HV CD had increased sporulation [213]. It is not improbable to suggest 
that the rate of sporulation may contribute to the spread and persistence of HV CD.  
The research described in this work more clearly defines the factors involved 
in hypervirulence, by determining the course of toxin production and sporulation in 
HV strains over the growth cycle. 
Colonization and Adherence 
Colonization and animal models 
Clostridium difficile is unusual in that the animal model for the disease was 
delineated before the etiologic agent was discovered. In the early work of Bartlett in 
identifying C. difficile, it was noted that antibiotic-treated hamsters and humans 
shared the same symptoms and the presence of a Clostridial toxin in their gut contents 
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[214]. In the hamster, the cecum is the main site of CD proliferation, which can be 
become dilated and hemmorrhagic [215], and also exhibits a loss of epithelium 
consistent with pseudomembranes [215]. 
Colonization is key for CDI to occur. Unlike C. botulinum, which can cause 
disease from the ingestion of botulinum toxin in food, CD has to colonize the gut to 
produce appreciable toxins, and most frequently begins with the ingestion of spores. 
Early work also noted that animals treated with antibiotics frequently became 
colonized with CD strains from the environment. If the contaminating strain was non-
toxigenic, further inoculations of toxigenic CD did not result in colonization of that 
strain or disease [216-218]. 
This observation of a competition effect has been further characterized and 
refined by the laboratory of Dale Gerding, who has patented the use of certain non-
toxigenic strains as a preventative treatment for human patients. Colonization is also 
key in the protection effect. In the hamster, when detectable colonization of the non-
toxigenic strain is achieved, protection from challenge by a toxigenic strain occurs in 
80-100% of animals [95, 219-221]. This is true even for challenge with hypervirulent 
strains [222]. 
Competition between mucosal bacterial species is common. As mentioned in 
the sporulation section, the mechanism by which the gut biota normally excludes CD 
is becoming better defined. Intra-species competition, such as seen in the protection 
effect, also occurs. For example, resident Staphlococcus aureus in the respiratory 
tract is able to exclude other S. aureus from colonizing, even when there is no 
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difference in fitness between strains [223]. Hypothesized mechanisms for intra-
species exclusion include monopolization of binding sites or essential nutrients [221, 
223]. However, the exact mechanism by which one CD strain excludes another is not 
defined. 
 Adherence 
Gut pathogens must associate with the mucosal epithelium to begin the 
process of pathogenesis. Compared to the wealth of information that has accumulated 
about the toxins, relatively little is known about the interaction of C. difficile with the 
gut. While the toxins are secreted and purifiable, investigations of molecules on the 
bacterial surface have been much more difficult, and have been limited by the lack of 
genetic tools available until recently. 
Once the hamster model of CDI was established, early work focused on strain 
differences in colonization factors. In 1988, Borriello examined strain differences in 
proliferation in various gut locations, and attempted to relate adherence to gross 
features such as flagella or fimbriae, but the conclusions that could be drawn were 
limited [224]. In 1991, Gonzalez-Valencia [225] attempted to correlate CD obtained 
from symptomatic or asymptomatic patients with the adherence to HEP2 cells in 
culture. Results were inconclusive, which is not surprising considering the multiple 
intrinsic and extrinsic factors that determine a patient’s symptomatic status. 
Multiple C. difficile adhesins have been described by the research group of 
Tuomo Karjalainen and Anne Collignon. Their early work found that heat-shocked 
CD grown in the presence of blood were more adherent than non-heat-shocked [226], 
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but the blood effect later turned out to be an error [227]. The heat labile protein 
identified by antigenic screening of a CD genomic library was a 27 kD adhesin that 
was not characterized further [226]. Other putative adhesins identified by this group 
have been the flagellin FliC, the flagellar cap FliD [228], and a fibronectin-binding 
protein Fbp68 [229], a heat-shock protein, GroEL [230]. Adherence of CD is reduced 
in the presence of anti-GroEL antibodies [230], although heat shock proteins are not 
usually displayed on the bacterial surface, so the mechanism for this effect is 
unknown.  
The best characterized adhesins so far are two; the surface associated adhesin 
Cwp66 [231], and the surface layer protein SlpA [232-234]. Cwp66 was first 
described as a heat-shock induced adhesin [231] that is located on the surface [182, 
235]. Initial work indicated that it was transcribed in early log phase [236], although 
later work reported that it was still highly transcribed in overnight cultures, and could 
be up-regulated by osmotic stress or the presence of antibiotics [237]. 
The S-layer protein SlpA was first described as one of a number of putative-
surface associated genes located in a cluster of 17 ORF’s along with cwp66 (Figure 6) 
[238]. These genes share homology to the cell-wall anchoring domain of CwlB/LytC 
of B. subtilis, indicating that these genes most likely code for surface-associated 
proteins [238] .  
S-layer proteins are secreted by many bacterial species and self-assemble into 
an ordered lattice on the cell surface. In addition to providing structural integrity to 
the cells, and acting as molecular sieves, S-layer proteins have been implicated in 
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adherence and immune evasion [239]. S-layer proteins have been demonstrated to be 
responsible for the adherence to the epithelia in several species of Lactobacilli [240, 
241]. S-layer proteins were the first prokaryotic proteins demonstrated to be true 
glycoproteins [242]. On the bacterial surface, glycosylation can have multiple 
functions, including stability, and evasion of the immune system of the host by 
blocking complement mediated lysis [243-245] [246].  
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Figure 6. Arrangement of genes containing slpA and its paralogs (ORFs 1–12) from 
CD strain 630. Black shading indicates regions of homology to the cell wall binding 
domain, and the non-homologous regions are shown in white. Dark grey indicates 
non-surface associated genes. Figure adapted from A. Wright et al. 2005. 
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The C. difficile S-layer protein SlpA is unique in that it contains two subunits 
[247], the high-molecular weight (HMW) and the low molecular weight (LMW) 
proteins, which are cleaved from a common precursor by the surface-associated 
protease Cwp84 [248] [234], and assemble on the bacterial surface into the 
paracrystalline lattice [247] . Because it covers the whole surface, SlpA is the most 
abundantly produced protein in the cell. The interaction of the two SlpA subunits is 
so robust that they assemble into lattices in vitro after denaturation and renaturation 
[249]. The crystal structure of the LMW subunit from strain 630 has recently been 
solved, along with a solution structure model of the two subunits interacting with 
each other [250] (Figure 7). The two subunits associate with each other with high 
affinity through the N-terminal of HMW subunit and the C-terminal of LMW subunit. 
Characterized as an adhesin by Neil Fairweather’s group, studies have shown 
that recombinant SlpA proteins bind to host tissues and extracellular matrix (ECM) 
proteins, and that CD adherence is decreased in the presence of anti-SLP antisera 
[232]. Concerning the relative function of the two subunits, Takeoka [247] has shown 
that both subunits are displayed on the exterior surface using immunogold electron 
microscopy. Takumi [249] found that antibodies to the LMW subunit reduced 
adherence more than antibodies to the HMW subunit. In contrast, Calabi [232] found 
that recombinant HMW subunit protein bound to gastrointestinal tissue while the 
LMW subunit did not, and that antibodies to the HMW subunit inhibited binding of 
the protein to Hep2 cells. 
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Figure 7. Fig. 7. Small-Angle-X-ray-Scattering (SAXS) structure of C. difficile SlpA 
from strain 630. A and B. Two orientations, differing by a 90° rotation, are shown of 
the complex of the HMW (red) and LMW (white) subunits. B. Model of the 
orientation of the HMW and LMW SLPs on the surface of C. difficile. The SAXS 
structure of the complex is shown as above with a ribbon representation of the LMW 
crystal structure overlaid in blue. The HMW SLP is also shown interacting with the 
cell wall; however, the extent and exact nature of this interaction is currently 
unknown. Figure and description adapted from Fagan et al, Mol. Micro. 2009. 
N 
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While it was initially appeared that SlpA was glycosylated, and this 
modification was hypothesized to influence host interactions, [234], later work using 
mass spectrometry definitively demonstrated that SlpA was not glycosylated, and that 
previous results were most likely due to SlpA preparations contaminated with 
peptidoglycan [251].  
This work investigated the interaction between hypervirulent C. difficile and 
the epithelia, and characterized one of the surface proteins, SlpA, that mediates this 
interaction.  
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CHAPTER TWO 
MATERIALS AND METHODS 
 
C. difficile Strains and Media  
C. difficile human clinical isolates were obtained from the culture collection of 
Dr. Dale Gerding (Table 1). Four HV C. difficile strains isolated from geographically 
distinct regions were chosen, as was BI-1, a historical isolate from the BI genetic group 
that predates the epidemics. The non-HV toxigenic strains included strain 630, the first 
fully sequenced strain, and strain VPI 10463, a known high-toxin producer [213], which 
are both very rarely found in clinical settings.  Strains J9 and K14 (representative of the 
REA type J and K groups respectively) have caused hospital outbreaks, are frequently 
isolated from hospital settings in the USA, but have never been reported as a cause of 
increased CDI severity and are not referred to as ‘hypervirulent’ [95, 189, 192, 200]. 
Strains M3, M23 and T7 are non-toxigenic. 
 
Table 1 C. difficile strains used in this study. 
Strain Source Year Source Toxigenic Hypervirulent 
630 Patient 1982 Switzerland Yes No 
VPI 10463 Patient 1980 Eastern USA Yes No 
J9 Patient 1987 Illinois Yes No 
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J32 Patient unknown unknown Yes No 
K14 Patient 1994 Illinois Yes No 
K29 Patient unknown unknown   
BI-1 Patient 1988 Minnesota Yes No 
BI-6 Patient 2003 Oregon Yes Yes 
BI-8 Patient 2004 Maine Yes Yes 
BI-17 Patient 2004 Montreal Yes Yes 
BI-23 Patient 2007 Eastern USA Yes Yes 
BI-moxi Patient unknown unknown Yes Yes, 
Moxifloxacin  
susceptible  
M3 Asymptomatic 
patient 
1989 Minnesota No No 
M23 Asymptomatic 
patient 
1991 Minnesota No No 
T7 Asymptomatic 
patient 
1986 Minnesota No No 
 
 
All strains were routinely cultured in Brain-Heart Infusion (BHI) Broth or on 
BHI-agar plates (Difco, Buchs, Switzerland; 37g/L) in a Coy anaerobic chamber 
(Grasslake, MI) with 5% CO2, 5% H2 and 90% N2.  For all assays, C. difficile strains were 
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grown to saturation in brain-heart infusion broth (BHI, BD Biosciences, Boston, MA) 
overnight. 1 ml aliquots were clarified by centrifugation at 2000xg. Bacterial pellets were 
washed in phosphate-buffered saline (PBS), resuspended in fresh BHI broth at a ratio of 1 
to 50, and allowed to grow without agitation under anaerobic conditions (90% N2, 5%H2 
and 5% CO2) in a Coy glove-box (Coy, Grasslake, Michigan). Identical inocula were 
used for all strains and all growth experiments. For growth curves, optical density 
readings (600 nm wavelength) were taken at intervals of one hour or less for the first 18 
hours, and again at 24 and 48 hours. 
E. coli Strains and Media 
Unless indicated otherwise, Escherichia coli strains (Table 2) were grown in Luria-
Bertani (LB) broth (1% w/v tryptone, 0.5% w/v yeast extract, 1% sodium chloride). For 
selection purposes during cloning and expression the following antibiotics were used at 
the following concentrations in liquid and solid media: Ampicillin, 200 ug/ml; 
Carbenicillin, 50 ug/ml; Kanamycin, 25 ug/ml; Chloramphenicol, 25 ug/ml. 
 
Table 2. E. coli strains used in this study 
Strain  Relevant characteristic(s)a Source or Reference 
E. coli Top-10 recA1, endA1 Invitrogen 
E. coli DH5α recA1, endA1 Invitrogen 
E. coli Rosetta Bl-21 derivative; pRARE plasmid 
contains 9 tRNA genes for rare codon 
expression 
Novagen 
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Anaerobic Bacterial Adherence Assay 
To quantitate CD attachment to human host cells, I devised an anaerobic bacterial 
adherence assay using a derivative of the Caco-2 human intestinal epithelial cell-line, 
Caco-2BBE. C2BBE host cells were cultured in high-glucose (25mM) Dulbecco’s 
Modified Eagle Medium (DMEM), 10% fetal bovine serum, 20mM HEPES, 100 IU/ml 
penicillin, and 100 mg/ml streptomycin at 37°C in the presence of 5% CO2.  Cells 
between passages 25 and 45 were grown to confluent monolayers (1.2x106 cells) in 6-
well plates, and transferred to antibiotic and serum-free DMEM 24 hours prior to 
adherence assays. All assay solutions were pre-reduced in the anaerobic chamber 
overnight. DMEM with 25mM CaCl2 was made by by adding 1 mL of 1M CaCl2 to 40 
mL of DMEM immediately before introduction to the anaerobic chamber. For the assays, 
C2BBE plates were introduced into the anaerobic chamber just before use, serum-free 
medium was removed, and exponential phase C. difficile applied at a multiplicity of 
infection of 20 in a total volume of 2mL DMEM. All bacterial strains used were washed 
and resuspended in anaerobic DMEM with 25mM CaCl2 (800 uL into 10 mL of DMEM) 
prior to incubation with host cells. 1 ml of DMEM with 25mM CaCl2 was applied to all 
wells, and and additional 1 mL of inoculum was added to test wells and 1mL of DMEM 
with 25mM CaCl2 to control wells. 
Adherence was allowed to proceed under anaerobic conditions for 40 minutes. 
Host cells and adherent bacteria were then washed twice with 1mL of anaerobic 
phosphate-buffered saline (PBS), scraped, serially diluted and plated to enumerate 
adherent C. difficile. Each experiment was performed in quadruplicate, and repeated at 
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least three times in entirety. The percent adherence was calculated as the ratio of 
recovered C. difficile to input C. difficile multiplied by 100.  
C2BBE cells survive the anaerobic conditions under which our experiments were 
performed, as confirmed by Live-Dead staining (Invitrogen).  
Immunofluorescence Microscopy 
C2BBE monolayers were grown on 12mm-diameter coverslips. Cells were placed 
in antibiotic- and serum-free cell culture medium containing 50% DMEM, 50% F-12, 
1.2% sodium bicarbonate, 3.56% HEPES, and 0.5% mannose overnight and then used in 
anaerobic adherence assays as described above. For immunofluorescence staining, 
infected monolayers were rinsed in PBS and then fixed in 3.75% paraformaldehyde for 
15 minutes. Fixed cells were quenched with PBS containing 75mM NH4Cl and 20mM 
glycine for 15 minutes. Cells were then washed twice in PBS and permeabilized with 
PBS containing 0.5% TritonX-100 for 15 minutes. Cells were washed once more with 
PBS and blocked for 1 hour in 5% bovine serum albumin (BSA). For analysis of the zona 
occludens 1 (ZO-1) protein, monolayers were incubated with 1:50 dilution of the mouse 
anti-ZO-1 (Zymed Laboratories, South San Francisco, CA) for 1 hour and then probed 
with mouse-specific secondary antibodies coupled with Alexa Fluor 568 (Molecular 
Probes, Eugene, OR) for 1 hour at room temperature. For actin visualization, host cells 
were incubated with 1:100 dilution of BODIPY 558/568 phalloidin (Molecular Probes, 
Eugene, OR) for 30 minutes at room temperature.  For visualization of C. difficile, 
samples were incubated with 1:20 dilution of rabbit anti-Clostridial spp antiserum 
conjugated with FITC (ViroStat, Portland, ME) for 1 hour at room temperature. Stained 
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samples were mounted with Prolong Gold Antifade Reagent (Molecular Probes, Eugene, 
OR) supplemented with 1ug/mL 4',6-diamidino-2-phenylindole (DAPI). A Leica 
DM4000B microscope (Leica, Wetzlar, Germany) was used for visualization, and images 
were documented using SlideBook 4.2 software (Olympus Imaging Systems, Center 
Valley, PA). All images were captured at a magnification of 1000X. 
Total Surface Protein Interference Assay  
Using the anaerobic adherence protocol described above, confluent C2BBE 
monolayers were incubated for 20 minutes (prior to the addition of bacteria) with DMEM 
plus equal volumes of PBS containing increasing amounts of purified, neutralized, 
dialyzed, anaerobic total surface-layer protein (SLP) preparations (isolation described 
below). Exponential phase C. difficile were then added to the monolayers, and adherence 
allowed to proceed for another 20 minutes as described above.  
Antibody Interference Assay 
Exponential phase C. difficile were resuspended in DMEM with 25mM CaCl2 and 
then incubated with anti-LMW SlpA or anti-HMW SlpA, or both, antisera at a dilution of 
1:1000 for one hour before addition to confluent C2BBE monolayers. Control 
experiments using C. difficile enumeration on BHI-agar plates were performed to confirm 
that there was no further growth/death of bacteria during this one hour incubation. 
Control antisera included anti-6-histidine antiserum (Qiagen, Valencia, CA), anti-TraG 
antiserum (an irrelevant E. coli conjugation protein, non-commercial) and an anti-
clostridial antiserum (Abcam, Cambridge, MA; antiserum does not contain C. difficile-
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derived antibodies) were used as controls in the resulting adherence assays (at dilutions 
of 1:1000 each). 
Total soluble protein isolation  
To obtain total cellular protein, bacteria were grown to exponential phase 
(O.D.600nm 0.5) in 37g/L BHI broth, harvested, and lysed by sonication (55% power; 12 
pulses of 15 seconds each). Cellular debris was removed by centrifugation at 6500g for 
30 minutes at 4°C. A protease inhibitor solution (EDTA-free Complete Cocktail, 1X final 
concentration, Roche, Indianapolis, IN) was added to the resultant supernate. This 
supernate was then centrifuged at 265,000g for 2.5 hr at 4oC to fractionate the sample 
into soluble proteins in the supernate and insoluble proteins in the pellet. The pellet was 
washed with PBS, and proteins dispersed with gentle sonication (45% power, 3 pulses of 
15 seconds each). Equal amounts (30ug) of total soluble proteins were subjected to SDS-
PAGE on 15% Tris-HCl gels (Biorad, Hercules, CA), and stained with Gel-Code Blue 
(Pierce, Rockford, IL) to visualize protein bands.  
S-layer protein extraction 
SlpA and other surface-layer proteins (SLPs) were extracted from multiple C. 
difficile strains using 0.2M glycine pH2.2, as described by Calabi et al [234]. Briefly, 
50mL of C. difficile culture grown in BHI was harvested at exponential phase by 
centrifugation (3000g for 20 minutes), washed in PBS, and resuspended in 200µl of 0.2M 
glycine pH2.2 and incubated at room temperature for 30 minutes. After centrifugation to 
remove the cell pellet (16,000g for 15 minutes at 4oC), the resultant supernate containing 
surface proteins (SLPs) was stored at -20oC until further use. SLPs used for adherence 
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interference assays were subsequently dialyzed into 10 volumes of PBS using 10kDa 
molecular weight cutoff centrifugation-based filters (Millipore, Billerica, MA). 
Protein Quantitation 
Total CD soluble protein, surface layer extracts, and recombinant protein were measured 
using the Bicinchoninic Acid (BCA) Protein Assay Kit (Pierce), according to the 
manufacturer’s instructions. A standard curve constructed using a gradient of known 
concentrations of bovine serum albumin (BSA) was prepared and tested for each 
assessment. 
DNA sequencing of slpA 
For sequencing, genomic DNA was isolated from exponential phase cultures 
using Qiagen DNeasy columns (Germantown, Maryland), according to the 
manufacturer’s instructions. DNA concentration was determined by a Beckman 
spectrophotometer, and DNA was aliquoted and frozen at –20oC. 
Since SlpA is highly variable, primers to amplify and sequence the slpA gene 
were designed inward from neighboring conserved regions. The upstream primer (slpAF: 
ATGTTGGGAGGAATTTAAGAAATG) was designed to include part of the conserved 
signal sequence of SlpA. The downstream primer (slpAR: 
ACCTCCACCAGTTTTCATCTCTGC) was designed inside of SecA [252]. 100 ng of 
genomic DNA was used as template for PCR reactions with primers at 40 pmol 
concentration. I used the Failsafe PCR system (Epicentre Biotechnologies, Madison, WI) 
consisting of the Failsafe Polymerase and a buffer mix (Buffer E) demonstrated to 
amplify C. difficile DNA. Reactions of 50ul volume were amplified for 32 cycles 
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including a 94°C denaturation step (30 seconds), annealing from 45-53°C (2 min), and a 
72°C extension step for 3 min. Annealing temperature were optimized for each strain 
using the temperature gradient feature of the BioRad i-cycler (Hercules, CA). PCR 
products were visualized using agarose gel electrophoresis, and purified by QiaQuick 
PCR purification columns (Qiagen, Germantown, MD), according to manufacturer’s 
instructions. If multiple bands occurred, the band of the appropriate size was gel purified 
using the Qiagen gel extraction kit. 20ng of purified PCR products were sent to the 
University of Florida Sequencing Core Laboratory. Each slpA gene from each strain was 
sequenced on both strands using initial amplification primers and subsequent primers 
derived from the sequences obtained. Sequence data was assembled and analyzed using 
Vector NTI software (Invitrogen, Carlsbad, CA).  
Immunodetection 
Western blotting experiments were performed on total soluble protein and surface protein 
extracts. 30ug of total soluble protein and 5ug of SLP extracts were electrophoresed on 
denaturing 4-20% gradient Tris-HCl acrylamide gels (Biorad, Hercules, CA) and 
transferred overnight to 0.45 uM nitrocellulose membrane at 50 volts using neutral 1x TG 
buffer (2.5 mM Tris-Cl, 19.2% Glycine) at 40C in a Trans-Blot cell (BioRad, Hercules, 
CA). Membranes were blocked for 1 hour at room temperature or overnight at 40C, using 
1% blocker from the Roche Western Blotting Kit. Primary antisera to the HMW and 
LMW SlpA subunits were used at 1:100,000 dilution. Primary antibodies were incubated 
for 60 mins in 0.5% blocker in TBS, at room temperature with shaking. Membranes were 
washed three times with TBST (50 mM Tris-Cl, 150 mM NaCl, pH 7.5 and 0.1% Tween 
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20) for 10 minutes. The secondary antibody was goat anti-rabbit IgG-POD conjugate 
(Roche, Indianapolis, IN). Secondary antibodies were incubated for 30 minutes, then 
washed for four times with TBST for 15 minutes. Proteins were visualized using the POD 
chemiluminescent detection system in the Roche Western Blotting kit according to 
manufacturer’s directions (Roche, Indianapolis, IN).  
Proteomic Identification of C. difficile Surface Proteins  
Surface protein extracts were electrophoresed using denaturing 4-20% Tris-HCl 
PAGE (Biorad, Hercules, CA) and stained with Coommassie Brilliant Blue. Bands of 
interest were excised, and proteins identified using liquid chromatography/mass 
spectrometry (LC/MS) analyses. All mass spectrometry analyses were performed at the 
University of Minnesota Mass Spectrometry Consortium. 
Molecular Cloning Techniques 
To produce recombinant subunits, the portions of slpA corresponding to the LMW 
subunit and the HMW subunit were each cloned individually from three CD strains 
(Figure 8). Based on the crystal structure of SlpA [250], I also designed a construct of the 
LMW subunit from strain 630 lacking the region required for interaction with the HMW 
subunit (Figure 7). Gene fragments were amplified from CD genomic DNA using the 
Failsafe PCR system (Epicentre Biotechnologies, Madison, WI) as described above. 
Using the Gateway System of entry and destination vectors (Invitrogen), amplified 
products were ligated into the entry vector pENTR/SD/D-TOPO. The entry vector was 
recombined with the destination vector pET-DEST-42, which contains an IPTG-inducible 
promoter, and a C-terminal V5 and 6x-histidine tag.  
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Figure 8. Schematic representation of slpA constructs cloned for the expression and 
synthesis of recombinant protein. 
 
Strain 630 
LMW truncated 
Strain K14 
Strain BI17 
LMW subunit 
LMW subunit 
LMW subunit 
HMW subunit 
HMW subunit 
HMW subunit 
  
Following subcloning into E. coli DH5α, pET-DEST-42 expression vectors with 
slpA constructs were transformed into Rosetta E. coli. The Rosetta strain of E. coli 
expresses several rare tRNA molecules that correct the codon bias of E. coli, making it 
more suitable for expression of C. difficile proteins. 
 
Table 3. Plasmids used in this work. 
Name Genotype/Description Reference 
pENTR/SD/D-TOPO Entry Vector, Kan+ Invitrogen 
pET-DEST-42 Expression vector, Amp+ Invitrogen 
pET-DEST-42-630LMW Strain 630 LMW subunit This work 
pET-DEST-42-630HMW Strain 630 HMW subunit This work 
pET-DEST-42-630LMWtrunc Strain 630 LMW subunit 
with 3’ truncation 
This work 
pET-DEST-42-K14LMW Strain K14 LMW subunit This work 
pET-DEST-42-K14HMW Strain K14 HMW subunit This work 
pET-DEST-42-BI17LMW Strain BI17LMW subunit This work 
pET-DEST-42-BI17HMW Strain BI17 HMW subunit This work 
 
Purification of recombinant proteins 
The conditions for recombinant protein synthesis and purification differed for 
different constructs. Briefly, Rosetta E. coli containing the constructs was grown and 
induced using Novagen Overnight Express Autoinduction Terrific Broth (TB) medium. 
Following induction, bacteria were pelleted by centrifugation, and frozen at -80o C. 
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Pellets were later lysed using Bugbuster (Novagen) in the presence of protease inhibitors 
(EDTA-free Complete Cocktail, 1X final concentration, Roche, Indianapolis, IN). For the 
LMW subunit of 630, recombinant protein was purified from the soluble fraction of cell 
lysates using cobalt affinity chromatography (Talon-spin columns, Clontech). The HMW 
subunit of 630 and the LMW subunit of K14 both degraded in the soluble fraction, so 
these constructs were isolated from the insoluble fraction, based on the protocol of Fagan 
et al [250]. Briefly, cell pellets were lysed using BugBuster lysis buffer (Novagen), and 
insoluble protein from inclusion bodies was purified according to manufacturer’s 
directions. These inclusion bodies were dissolved in 8M urea, 150mM NaCl 10mM 
HEPES, and subjected to cobalt affinity chromatography. The purified recombinant 
proteins were refolded by step-wise dialysis to native buffer conditions (150mM NaCl 
10mM HEPES). This method yielded soluble refolded proteins.  
The K14 HMW construct degraded extensively in E. coli, so I employed an 
alternate approach to isolate this subunit from C. difficile surface extracts. Surface 
proteins were extracted from an exponential phase culture of strain K14 using the acid-
glycine method described above. These extracts were mixed with 8M urea and Laemmli 
loading buffer, heated at 70 oC for 15 minutes and subsequently electrophoresed in an 
SDS-PAGE gel. Portions of the unstained gel corresponding to the HMW subunit were 
excised, minced, and placed in the vertical tubes of a BioRad electroelution apparatus, 
and allowed to migrate out of the gel slices over three hours. The electro-eluted protein 
solution was dialyzed against native buffer to remove SDS, denatured in 8M urea and 
refolded as described above.  
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Recombinant SlpA Protein Interference Assay 
For technical reasons, I used the parental Caco2 cell line, which exhibits similar 
adherence to the Caco2-BBE line (not shown). To conserve recombinant protein, 
volumes were scaled down to conduct the assay in 24 well rather than 6 well culture 
plates. Similar to the Total Surface Protein interference assays described above, confluent 
Caco2 monolayers were incubated for 20 minutes (prior to the addition of exponential 
phase strain 630 bacteria) with 250 uL DMEM plus 25mM CaCl2 and 250 uL of 150mM 
NaCl 10mM HEPES buffer containing increasing amounts of anaerobic recombinant 
protein. Exponential-phase C. difficile (MOI 20, 250 uL volume of inoculm prepared as 
described above) were then added to the monolayers, and adherence allowed to proceed 
for another 20 minutes as described above. 
Toxin ELISA  
For toxin testing using an ELISA, culture samples were clarified, and supernatant 
fluids were sterile filtered and frozen at -80oC prior to use. All growth experiments were 
performed in entirety at least three times. For toxin quantitation, culture supernatant 
fluids were collected at mid-exponential phase (OD600 of 0.5), early stationary phase 
(defined by two consecutive non-increasing OD600 readings; about 10-12 hours), mid-
stationary phase (15hrs), and at 18, 24, and 48 hours of growth.  
Toxin amounts were quantitated using the Wampole Tox A/B II kit (TechLabs, 
Inc, Blacksburg, VA). Purified Toxin B (provided by TechLabs, Inc) was used to 
construct a standard curve. Samples of the supernatant fluids were diluted to fall within 
the linear range of the standard curve, and this dilution was used to calculate the amount 
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of toxins present. All samples were tested in triplicate, and each experiment performed in 
entirety at least three times.  
RNA Isolation and cDNA synthesis 
For toxin gene expression assays, total RNA was isolated from exponential phase 
(OD600nm = 0.5) and stationary phase (12 hours) cultures. Five milliliters of culture were 
harvested by centrifugation at 2800xg for 10 minutes at 4°C. Bacterial pellets were 
processed immediately or resuspended in lysis buffer, flash-frozen in liquid nitrogen and 
stored at -80°C. Lysis and extraction of RNA were performed using the Ambion 
RiboPure Bacteria RNA kit (Ambion, Austin TX) according to the manufacturer’s 
instructions, followed by DNaseI digestion using Ambion Turbo DNase. DNaseI 
digestion was repeated twice for all samples. The RNA obtained after each DNaseI 
digestion was purified using the Qiagen RNeasy RNA column purification kit, according 
to the manufacturer's instructions (Qiagen, Germantown, MD), quantitated using a 
NanoDrop spectrophotometer, aliquoted and stored at -20o C. RNA quality was assessed 
spectrophotometrically (260/280 nm) and by visualization on denaturing 
formamide/formaldehyde gels (not shown). 500 ng of pure RNA from each sample was 
converted to cDNA using random hexamers and the BioRad iScript cDNA synthesis kit 
(Biorad, Hercules, CA).  
Quantitative Real-time PCR.  
Primers used to amplify PaLoc genes are shown in Table 4, and were either 
synthesized using previously published sequences (for tcdA, non-HV strain tcdB, and 
tcdC; [103], or specifically designed for HV strain tcdB as well as for tcdR and rpoA. 
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Table 4. Primers used in this study for Quantitative Real-time PCR. 
 
Primer Name Primer Sequence 5’ to 3’ Purpose 
JRP3443Aup  
 
GTCGGATTGCAAGTAATTGACAATA tcdA-specific 
forward 
primer 
 
JRP3444Adn  
 
TAACAGTCTGCCAACCTTTTGAGA tcdA-specific 
reverse primer 
JRP4055Bup ACCATATAGCTTTGTAGATAGTGAAGGAAA tcdB-specific 
forward 
primer non-
HV strains 
 
JRP4056Bdn AAGAACTACATCAGGTAATTCAGATACAAA tcdB-specific 
reverse primer 
Non-HV 
strains 
tcdB4BIup AGCTGCTTCAGTCGGAGAAA tcdB-specific 
forward 
primer HV 
strains 
 
tcdB4BIdn AATCAATTGCTTCCCCCTCT tcdB-specific 
reverse primer 
HV strains 
JRP4053Cup AGGGTATTGCTCTACTGGCATTTATT tcdC-specific 
forward 
primer 
 
JRP4054Cdn CCTCATGGTCTTCAGAACAAGCT tcdC-specific 
reverse primer 
tcdR3up ATCAAAGTAAGTCTGTTTTTGAGGAAG tcdR-specific 
forward 
primer 
 
tcdR3dn TGCTCTATTTTTAGCCTTATTAACAGC tcdR-specific 
reverse primer 
rpoA2up TCATTACCAGGTGTAGCAGTGAA rpoA-specific 
forward 
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primer 
 
rpoA2dn GAGCATGGTCCTTGAGCTTC rpoA-specific 
reverse primer 
 
All primers were tested in genomic DNA amplification for all test strains to 
confirm specificity and amplicon size, before use in quantitative reverse-transcriptase 
(qRT) PCR reactions. To test for DNA contamination, RT-PCR reactions were performed 
for all samples using RNA alone, and found to be negative (not shown). Expression 
levels of all PaLoc genes tested in each isolate were normalized using the C. difficile 
housekeeping gene rpoA as a reference [102]. Transcription rates for individual PaLoc 
genes relative to each other among different isolates were not determined since the 
efficiency of reverse transcription varies for different genes, making between-gene 
transcription rate comparisons inaccurate. 
A gradient of C. difficile genomic DNA was used to determine the efficiency of 
amplification of each primer set. Efficiencies ranged from 90-101% and R2 values were 
at least 98%. For all samples tested, 25 ul reactions were performed in triplicate using 
5PRIME Real Master mix SYBR ROX (Fisher, Pittsburgh, PA), 1 µl of cDNA, and 250 
nM primers in an Eppendorf MasterCycler equipped for qRT-PCR detection [102]. 
Specificity of product was determined by dissociation (melt) curve analysis. PaLoc gene 
expression was analyzed relative to that of the reference gene using the ∆Ct method, 
according to the following formula: 2CtRef – CtTest [253]. 
Sporulation Assays.  
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To assess the presence of spores over time, I employed plating and microscopy. 
At 8, 20, 28, and 48 hours post-inoculation, 1 mL samples of each strain tested were 
clarified by centrifugation, bacterial pellets washed in PBS, heat-shocked at 65oC for 15 
minutes (to kill vegetative cells), serially diluted and plated on taurocholate (a spore 
germinant) fructose agar (TFA) plates to enumerate spores [221]. Plates were incubated 
anaerobically for 48 hours, after which CFUs were enumerated.   
For microscopy, 10 uL samples of 48 hour cultures were applied to microscope 
slides, oven-dried at 85 oC for 5 minutes, and Gram-stained. Spores were defined as all 
refractile bodies, whether free or still attached to mother cell material. For each strain, ten 
distinct fields were photographed and enumerated at 100X magnification under oil-
immersion. 
Statistical Analyses 
The SPSS (SPSS, Chicago, IL) and StatView (SAS, San Francisco, CA) software 
packages were used for statistical analyses. Significance was determined using analysis 
of Variance (ANOVA) to enable comparison between multiple groups of continuous 
numerical data. The Protected Least Significant Difference test was used for posthoc 
analyses.  
  
 
CHAPTER THREE 
RESULTS 
 
The Adherence of CD to Host Cells and the Role of SlpA in this Interaction 
Introduction 
From the perspective of a commensal bacterium, the gut is a rich but unstable 
environment. To avoid being completely shed in the fecal stream by the action of 
peristalsis, bacteria must adhere to the host.  Adherence can be direct between the 
bacterium and the host cell, or extracellular structures such as biofilms can accomplish 
this task. As an opportunistic pathogen, C. difficile faces the same problem. Additionally, 
if CD produces toxins to destroy host cells for the purpose of extracting nutrients, they 
must maintain proximity to host epithelia to do so. If adherence is an adaptation, are more 
adherent strains more successful? In particular, if hypervirulent CD strains are successful 
pathogens, do factors in colonization or adherence contribute to this phenotype?  
To investigate the role of non-toxin proteins in hypervirulent strains, my approach 
was to examine colonization using an in vitro model and, in tandem, to examine total 
protein profiles, and discover factors that might vary in hypervirulent strains.  
To achieve this first goal, I developed an anaerobic assay to test the adherence of 
C. difficile strains to human intestinal epithelial cells grown in culture. For in vitro 
studies, few reports appear in the literature for which live, whole C. difficile bacteria have 
been used. For example, most studies exploring C. difficile attachment to host epithelia 
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have been performed using non-intestinal cell lines, and under aerobic conditions that fail 
to recover viable bacteria [227, 230, 254].  
At the molecular level, mechanisms of C. difficile pathogenesis have been 
difficult to elucidate since the organisms are not readily genetically tractable. C. difficile 
cannot be reliably electroporated or transformed, and conjugation-based methods of DNA 
introduction into C. difficile have been hampered by lack of suitable cloning vectors, and 
the presence of restriction/methylation barriers that hinder heterologous DNA 
maintenance [255, 256]. In recent years, two genetic tools for C. difficile gene disruption 
have been developed, one based on an unstable C. perfringens vector and another based 
on a targetable Group II intron [102, 257]. While these tools represent a watershed 
advance in CD research, they were not well developed at the initiation of this work. 
Further, these tools are not suitable for genome-wide genetic screens. Given these 
limitations, we decided to use a protein-based approach to initially identify unique and 
divergent proteins that might be involved in hypervirulence.  
C. difficile strains differ in adherence to host epithelia in culture 
Using immunofluorescence microscopy, I visualized the adherence of bacteria 
with host cells, as shown in Figure 9.  Bacteria are distributed over the whole monolayer, 
and do not seem to be associated with particular structures such as the cell-cell borders. 
This assay also confirmed host cells exhibited morphology consistent with viability under 
anaerobic conditions (well rounded nuclei with uniform staining, normal actin stress 
fibers and uniformly distributed ZO-1 around host-cell peripheries). 
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Figure 9: Microscopy-based visualization of C. difficile adherence. Bacteria 
(green) were stained with anti-clostridial sp antiserum conjugated to FITC; host-cell 
nuclei (blue) were stained with 4',6-diamidino-2-phenylindole (DAPI), host cell actin 
(red) was stained with BODIPY 558/568 phalloidin (panel A) and host-cell ZO-1 (red) 
 B 
A 
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was stained with anti-ZO-I antiserum conjugated to Alexa Fluor 568 (panel B). Images 
shown were captured at a 1000X magnification, are representative of multiple fields 
visualized, and are from two independently performed experiments. 
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I began my comparison of HV strain to other toxigenic CD strains by developing 
a quantitative in vitro test of adherence to host cells. Hypervirulent strains were compared 
to the toxigenic but non-hypervirulent C. difficile strains K14, J9 and J32. As shown in 
Figure 10, I found that three out of five BI strains tested exhibited ≥100% higher 
adherence to C2BBE cells than toxigenic but non-hypervirulent strains (p≤0.0001). From 
these data, it appeared that hypervirulent C. difficile strains had increased adherence to 
human host cells. This was the first indication that non-toxin proteins, particularly those 
involved in bacterial attachment, might be different in these strains. 
  
 
  
 
 
 
 
 
 
 
 
 
Figure 10: Adherence of C. difficile strains to C2BBE monolayers. Three non-hypervirulent strains (K14, J9, J32) and five 
hypervirulent strains (BI-6, BI-8, BI-17, BI-23 and a moxifloxacin-susceptible BI isolate) were tested. Percentage adherence 
with standard error of the mean is depicted; all experiments were performed in quadruplicate, and repeated in entirety at least 
three times.  
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Adherence of CD strains over the growth cycle 
 The behavior of CD changes with nutrient availability. When nutrients are 
limited, bacteria begin to produce toxins. Does adherence of CD change over during 
different growth phases? To answer this question, I tested the adherence of several strains 
of CD during stationary phase. I determined the adherence of strains 630, K14 and BI17 
during exponential growth and during early stationary phase. Figure 11A shows the mean 
adherence of multiple independent assays. HV Strain BI17 showed a significant decrease 
in adherence in stationary phase (p<.05). Strain 630 showed a trend to decreased 
adherence (p=.07), while strain K14 did not appreciable decline. Figure 11B shows the 
means of single assays of four other strains, which also show trends to exhibit lower 
adherence in stationary phase in two (J32 and M3) of the four strains. 
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Figure 11. Adherence of C. difficile strains to C2BBE monolayers. A.Three strains 630, 
K14 and BI17 were tested at exponential phase and early stationary phase. Percentage 
adherence with standard error of the mean is depicted; experiments were performed in 
triplicate, and repeated in entirety two or three times. B. Adherence of four CD strain. 
Percentage adherence of a single quadrulicate assays are shown. 
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 Protein profiles of HV CD and the identification of SlpA 
In parallel, I wanted to discover other factor that might be different in HV CD as 
compared to toxogenic CD. To explore potential protein variation in hypervirulent C. 
difficile, I examined total soluble protein profiles of hypervirulent strains, as well as those 
of the toxigenic (but non-hypervirulent) C. difficile strains 630, J9 and K14. Total soluble 
protein profiles on SDS-PAGE gels were compared between strains. Bands that appeared 
to differ between strains were subjected to MALDI mass spectrometry analyses for 
protein identification.  One strong band that differed between strains was identified as the 
C. difficile Surface Layer (S-layer) protein SlpA. As shown in Figure 12A, a prominent 
protein band in the BI-6, BI-8 and BI-17 strains that appeared altered in amount 
compared to that of strains 630 and J9. If a surface protein was variable, this might be 
related to factors involved in colonization and host interaction.  
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Figure 12. C. difficile protein studies. Panel A: Total soluble protein profiles of C. 
difficile strains. 630, J9 and K14 are toxigenic (but non-epidemic strains); BI-6, BI-8 and 
BI-17 are hypervirulent strains. Arrows indicate bands excised for mass spectrometry 
analysis.  Panel B: Extracted surface-layer protein (SLP) profiles of C. difficile strains. 
Eleven BI-17 bands were identified by mass spectrometry (one round; peptide mass 
determination); identities of 7 bands and their Genbank Accession numbers are shown in 
Panel D. Panel C: Western blot analyses of SLP preparations from C. difficile strains. For 
all C. difficile strains tested, 30ug of total soluble and 5ug of SLP preparations were 
electrophoresed; antisera were used at a 1:100,000 dilution. 
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As mentioned earlier, S-layer proteins are secreted by many bacterial species and 
self-assemble into an ordered lattice on the cell surface. The C. difficile S-layer contains 
two subunits [247], the high-molecular weight (HMW) and the low molecular weight 
(LMW) proteins, which are cleaved from a common precursor, SlpA [234]. I extracted 
the C. difficile S-layer and other surface-associated proteins (SLPs) from multiple C. 
difficile strains using an acid-glycine method [234]. Figure 12 B shows the S-layer and 
other surface-associated proteins from the hypervirulent strains BI-6, BI-8 and BI-17 and 
also the toxigenic (but non-hypervirulent) K14 and 630 strains. I found that hypervirulent 
strains produced surface layer proteins that were distinct in both size and number from 
non-hypervirulent strains. The HMW S-layer protein appeared as a doublet of 
approximately 48kDa, and the LMW S-layer protein appeared as a doublet of 
approximately 30kDa. Western blotting experiments using anti-HMW SlpA and anti-
LMW SlpA antisera showed that the bands in the doublets were indeed SlpA (Figure 12 
C). The LMW subunit has been previously noted to vary more in size and antigenicity 
[233, 234, 252]. To complete this initial C. difficile surface protein analysis, several SLP 
bands were excised and subjected to MALDI mass spectrometry analyses, and showed 
that all were S-layer or surface-associated proteins of C. difficile (Fig. 12 D) which 
shared greatest similarity to those of the recently sequenced hypervirulent C. difficile 
strain from Quebec QCD-32g58 (Genbank accession #AAML00000000; GI:145694830). 
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Surface protein extracts block adherence of CD to host cells 
C. difficile SLP preparations have previously been demonstrated to adhere to host  
epithelial cells [232]. To determine if there was a link between SlpA and adherence of C. 
difficile strains, I employed two approaches: protein interference and antibody 
interference. First, I performed anaerobic adherence assays where confluent C2BBE 
monolayers were pre-incubated with increasing amounts total surface-layer (SLP) 
preparations (such as those used in Figure 12 B). There was a dose-dependent reduction 
in C. difficile adherence with increasing amounts of total SLP protein (up to 80% 
adherence inhibition; p≤0.0001) (Figure 13). This indicated that pre-incubation of 
C2BBE host cells with the total SLP preparation blocked adherence presumably by 
competing for a host-cell receptor(s). In control experiments, PBS alone or PBS with 
50ug bovine serum albumin did not interfere with C. difficile binding to C2BBE cells in a 
statistically significant manner. 
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Figure 13. C. difficile adherence interference assay using total SLP protein from strain 
BI-17 to coat C2BBE cells, and then testing adherence of the same strain (BI-17). For 
comparative purposes, data were converted to percent adjusted adherence, with adherence 
of the control strain set to 100%. Asterisks indicate significant differences in raw data (p 
≤ 0.01) 
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Surface protein interference is not strain specific 
In the hamster model of CDI, colonization with a non-toxigenic strain of CD 
efficiently prevents colonization by a toxigenic C. difficile strain (36), although the 
mechanism for this effect is not known. In addition to the array on the surface, SlpA is 
secreted into the extracellular milieu (Figure 14 A). Could the presence of SlpA provide a 
mechanism for this effect? To test if the adherence interference observed above was 
strain-specific, I used total SLP preparations in cross-interference of adherence assays. 
SLPs prepared from the phylogenetically unrelated (by multilocus and microarray 
analyses) non-toxigenic C. difficile strain M3 significantly inhibited BI-17 adherence, and 
SLPs from C. difficile strain BI-17 significantly inhibited M3 adherence (Figs. 14 B and 
C). The degree of inhibition was almost identical in both sets of assays (≥85%; 
p≤0.0001). 
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Figure 14. Panel A. Supernatants of CD indicate the presence of secreted SlpA Marker 
indicates kD Lane 1 Strain M3. Lane 2 Strain J9 Lane 3 Strain BI17. Panel B and C: 
Cross-interference of adherence with non-cognate SLP preparations. B.  Strain BI-17 
adherence tested on C2BBE host cells pre-adsorbed with total SLPs from either cognate 
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(BI-17) or non-cognate (M3) strains. C. Strain M3 adherence tested on C2BBE host cells 
pre-adsorbed with total SLPs from either cognate (M3) or non-cognate (BI-17) strains. 
All experiments were performed in quadruplicate. 
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Antibodies to SlpA interfere with adherence 
Surface extracts contain other proteins in addition to SlpA. To implicate SlpA 
specifically, I pre-incubated the C. difficile strain 630 bacteria with anti-LMW SlpA or 
anti-HMW SlpA antisera for one hour before addition to confluent C2BBE monolayers. 
These antisera were raised against strain 630 SlpA subunits specifically. The presence of 
both antibodies significantly reduced adherence by approximately 50 % (p<0.02), 
indicating that SlpA was indeed involved in C. difficile adherence (Figure 15, p≤0.0001). 
The presence of an irrelevant antibody to an E. coli protein, anti-TraG, did not 
significantly reduce adherence. While the antisera were not raised against the HV strain 
BI17, other assays indicated that both antibodies also significantly reduced the adherence 
of this strain (not shown). 
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Figure 15. Adherence interference assay using anti-SlpA antisera.  C. difficile strain BI-
17 incubated with a 1:1000 dilution of non-SLP or anti-SlpA antisera prior to exposure to 
C2BBE host cells. Adherence of strain 630 set to 100%. Means and standard errors of 
three replicates are shown. Anti-TraG antiserum acted as a negative control. 
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Survey of Multiple CD strains reveals wide range of adherence values 
Further work detailing the adherence of multiple C. difficile strains demonstrated 
a great range of adherence values, as shown in Figure 16. Genetic groups are not 
necessarily homogenous in adherence values. Across all strains, the mean adherence 
value was 6.39%. As a group, the hypervirulent strains exhibited a mean adherence value 
of 4.63%. 
  
 
  
 
Figure 16. - Adherence of multiple C. difficile strains to C2BBE monolayers. Strains in the same genetic group are shown in 
the same bar color. Percentage adherence with standard error of the mean is depicted; all experiments were performed at least 
in quadruplicate. 
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Sequencing of slpA from multiple Clostridium difficile strains. 
Even though further data indicated that HV strains were not markedly more 
adherent than other CD strains, investigating the contribution of SlpA to adherence 
remained interesting. I wanted to further characterize how SlpA mediates adherence, and 
to describe the variation in SlpA that may contribute to the increased adherence of some 
strains than others. 
Many slpA genes have been sequenced [233, 252, 258, 259], but observed 
variations have not been analyzed in the context of the genetic relatedness (both within 
and between genetic groups) or adherence phenotypes of the strains. I determined the 
sequence of the slpA genes of hypervirulent, toxigenic and non-toxigenic Clostridium 
difficile strains, so I could employ this data when evaluating SlpA function.  
I chose 4 strains from the hypervirulent clade: BI1, BI6, BI8 and BI17. BI1 is a 
historical isolate in the Gerding collection, which predates the hypervirulent epidemics. I 
also chose toxigenic strains J9 and K14, and two non-toxigenic strains, M3 and T7. As 
mentioned earlier, microarray data indicate that the HV strains cluster in the same clade, 
termed HY. Strains J9 and K14 fall into the HA1 clade. Non-toxigenic strains M3 and T7 
reside in a third clade, A-B+, which contains toxin variant and non-toxigenic strains.  
When comparing the HV strains to other CD strains, there were striking 
differences in slpA sequence identity, depending on the subunit. As shown in Figures 17 
and 18, the HMW subunit is more conserved in amino acid sequence, while the LMW 
subunit is more divergent. This is consistent with previous surveys of slpA [252]. The 
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LMW subunit shows areas of conservation at the N-terminal signal sequence for export, 
and in the C-terminal end involved in interaction with the HMW subunit. The HMW 
subunit is conserved over the whole subunit, consistent with its role as the peptidoglycan 
anchor. 
  
 
Figure 17.  Low Molecular Weight Subunit Alignment. Alignment of strains 630, K14, M3, J9 and BI17. Yellow indicates 
complete consensus, Blue indicates high consensus, Green indicates similar residue 
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Figure 18.  High Molecular Weight Subunit Alignment.. Alignment of strains 630, K14, M3, J9 and BI17. Yellow 
indicates  complete consensus, Blue indicates high consensus, Green indicates similar residue 
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Figure 19 shows the percentage of amino acid identity between strains, by 
subunit. Data indicate that the slpA sequence was identical (99-100%) at the amino acid 
level among the four HV strains. Strain J9, despite being in a different clade, showed the 
highest amount of sequence similarity to HV strains. The non-toxigenic strain M3 
showed the lowest amount of sequence identity, consistent with the phylogenetic 
divergence of non-toxigenic strains.  
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Figure 19. Sequence Analysis of SlpA subunits of 6 CD strains. A. LMW 
sequence identity. B. HMW sequence identity. Numbers indicate percent 
identity at the amino acid level.  
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SlpA binding to host cells of C. difficile SlpA subunits independently  
If SlpA mediates adherence, then it is reasonable to assume that one or both of the 
subunits should be able to mediate adherence. The conservation of the HMW subunit and 
the divergence of the LMW subunit may indicate a distinct function of each subunit. 
Further, is the variability in SlpA sequence responsible for increased adherence seen in 
some strains? To answer these questions, I assessed the contribution of recombinant SlpA 
subunits to adherence using protein interference assays. I chose strain 630 because it is 
highly adherent, (~10 %, see Figure 16), and strain K14 because it has a low level of 
adherence (~2%, see Figure 16). If SlpA plays a role in adherence, then the subunits of a 
highly adherent strain should affect adherence more than those of a less adherent strain. 
To produce recombinant subunits, the portions of slpA corresponding to the LMW 
subunit and the HMW subunit from CD strain 630, and the LMW subunit from strain 
K14 were each cloned individually and expressed in E. coli and purified (Figure 20). The 
HMW subunit from strain K14 was purified from C. difficile surface extracts. In the 
protein interference assays, confluent Caco-2 monolayers were pre-incubated for 20 
minutes with increasing amounts of recombinant SlpA subunits. Exponential phase strain 
630 C. difficile were then added to the monolayers, and adherence was allowed to 
proceed for 20 more minutes.  
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Figure 20. A. SlpA crystal structure, adapted from Fagan et al 2009. B. Recombinant 
proteins from strains 630 and K14 synthesized and characterized in this work. 
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The results obtained with the recombinant subunits correlate well with the 
antibody interference studies, which indicate that both subunits play a role in adherence. 
The presence of recombinant protein decreases adherence in a dose-dependent manner, 
but the degree of decrease differs for the subunits from different strains, as shown in 
Figure 21. From the range of values, I calculated the 50% Inhibitory Concentration 
(IC50) of each subunit, as shown in Table 4. Trends in the data suggest that the LMW 
subunit has a greater impact on adherence. Strain 630 is highly adherent, and the 
recombinant 630 LMW showed the lowest inhibitory concentration. Strain K14 exhibits a 
low level of adherence, and the IC50 values of K14 recombinant subunits reflect this. 
However, because of the limited number of observations, especially for the K14 subunits, 
the confidence intervals of the curves for each subunit overlapped, indicating that they 
are not significantly different. 
 
Table 5. Inhibitory concentrations producing a 50% decline in adherence. 
Strain and Subunit 630 LMW 630 HMW K14 LMW K14 HMW 
Non Linear IC50 1.1 uM 3.7 uM 2.2 uM 4.4 uM 
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Figure 21. Adherence of strain 630 in the presence of recombinant LMW or HMW SlpA 
subunits from strains 630 or K14. Each dot indicates the mean of one triplicate test. 
Conditions with buffer alone were set to 100% adherence. Curves indicate non-linear 
least squares fit. 
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Summary 
C. difficile strains vary significantly in their ability to adhere to host cells. The surface 
protein SlpA varies significantly between strains, and the antibody and protein 
interference experiments suggest that SlpA is involved in C. difficile adherence. Antibody 
interference and recombinant protein interference studies indicated that both subunits are 
involved.  
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Toxin Production and Gene Expression in Hypervirulent C. difficile 
Introduction 
As mentioned earlier, toxins are produced in stationary phase in response to 
nutrient limitation [151]. The increased morbidity and mortality associated with HV CDI 
[5] first suggested that toxin production might be increased. This hypothesis was first 
tested in vitro by Warny et al, using ELISA to determine the levels of toxin production in 
a group of HV and non- HV strains [194]. They found that the median values of toxins A 
and B were 16 and 23 fold higher, respectively, than the median (not mean) for a group 
of non-HV strains. They measured toxin production at 0, 24 and 48 hours, and concluded 
that the high amounts of toxin accumulated by 24 hours were produced in exponential 
phase, though their growth curves do not define the inflection points of a typical sigmoid 
growth curve.  
 Taken at face value, this interesting result had the potential to be useful to our 
characterization of HV CD. If toxins were produced in exponential phase, this could 
serve as a positive control in investigating the overall proteome differences in HV strains 
by Stable Isotope Labeling of Amino Acids in Culture (SILAC), an approach not detailed 
in this work. However, I was unable to replicate the production of toxin during 
exponential phase by HV strains. Using a commercial ELISA for both toxins, I found no 
toxin present in supernatant from an HV strain. This discrepancy led me to want to 
systematically define the production of toxin by HV strains over the growth cycle, to 
determine if toxin production occurred earlier in the growth cycle, and determine if levels 
are increased when mean rather than median values are used for analysis. 
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To answer these questions, I performed growth curves and tested samples of 
supernatant collected over the whole growth cycle and subjected them to ELISA for 
toxins A and B. If toxin production were indeed dysregulated in HV strains, then I would 
expect to see toxin production during a well-defined exponential phase. I compared four 
HV strains to four non-HV strains. The non- HV strains included strain 630, the 
sequenced strain and a known low toxin producer, and strain VPI 10463, a known high-
toxin producer, and strains, J9 and K14, which have been associated with previous 
outbreaks, [95, 189].  
Hypervirulent CD strains do not secrete toxins during exponential growth 
HV strains showed no statistically significant growth defects or advantages over 
non-HV strains (Figure 22 A). Some strains exhibited a steeper decline in optical density 
readings in late stationary phase, but this finding was not consistent or specific to HV or 
non-HV strains. 
Evaluation of toxin production by ELISA indicated that no toxin was detectable 
during the exponential phase of growth for all strains tested (Figure 22 B). The sensitivity 
of the ELISA is approximately 0.8 ng/ml for Toxin A and 2.5 ng/ml for Toxin B. The 
highest toxin producer was the non-HV strain VPI 10463 (~2000 ng/mL total toxin at 48 
hrs). Toxin began to accumulate in culture supernatant fluids between 12 and 15 hours in 
VPI 10463 as well as in three of the HV strains. For all strains tested, the majority of 
toxin accumulated between 24 and 48 hours. When averaged, there were no statistically 
significant differences between the group of four HV strains and the four non-HV strains. 
At 24 and 48 hours, strain VPI 10463 exhibited significantly higher toxin production than 
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all other strains. At 24 hours, BI8 was significantly higher than strains 630, J9 and BI23. 
Interestingly, while strain BI23 was significantly lower than BI17, BI8 and VPI 10463 at 
24 hours, at 48 hours, it was significantly higher than all strains, other than VPI 10463. 
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Figure 22. A. Growth curves of the eight strains used in this study. Absorbance at 
600nm wavelength measured over 72 hours of growth. B. Total toxin levels over time. 
Toxin levels indicate combined TcdA and TcdB levels by ELISA. Exponential Phase 
samples were taken when each individual culture reached an OD600 of 0.5. Means and 
standard error from three biological replicates are shown. The sensitivity of the ELISA is 
approximately 0.8ng/ml for TcdA and 2.5ng/ml for TcdB.
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PaLoc Gene Expression Over the Growth Cycle 
The previous data address the production of secreted Toxin A and Toxin B 
proteins in combination. If both were undetectable by ELISA, then one would assume 
that gene expression is similarly repressed, and that high toxin production in stationary 
phase would be correlated with high gene expression. However, each toxin may be 
produced in differing amounts, and protein synthesis and gene expression are not 
perfectly correlated. Also, I wanted to determine the expression of tcdR and tcdC over the 
growth cycle. Given my preliminary data, I hypothesized that the lack of TcdC, the 
negative regulator, would not be sufficient to account for toxin production during 
exponential growth, because transcription of the toxin genes requires TcdR and is also 
dependent on other stationary phase regulatory factors such as CodY [122, 125]. 
To test my hypothesis, I performed transcriptional analyses of 4 PaLoc genes over 
the growth cycle. I examined the transcription of the two toxin genes, tcdA and tcdB, and 
the regulatory factors tcdC and tcdR, in the 8 strains of CD, during exponential versus 
stationary phase, to distinguish between two possible effects of TcdC truncation on the 
production of Toxins A and B: dysregulation in exponential phase, and increased levels 
in stationary phase.  
HV strains exhibit high tcdA and tcdB expression 
Transcriptional analyses using quantitative real-time PCR were performed on all 
eight strains tested above for both tcdA and tcdB, as well as for the regulatory factor-
encoding genes tcdC and tcdR, at both exponential and early stationary growth phases. 
Based on the ELISA data, I expected that the expression of tcdA and tcdB in all strains 
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would be low/undetectable in the exponential phase of growth, and high in stationary 
phase, and this was indeed the case. The levels of the rpoA reference gene expression 
were comparable across all strains in the same growth phase. Overall levels of rpoA 
transcription were higher in exponential phase than in stationary phase, as would be 
expected under rapid growth conditions. 
For tcdA, and consistent with the expectation described above, low levels of 
expression were observed during exponential growth (Figure 23 A). Levels of detectable 
tcdA transcripts were, on average, 100-fold lower than those of rpoA (the reference gene) 
and were not significantly different between HV and non-HV strains as a group. If tcdA 
expression were dysregulated in exponential phase, one would expect to see much higher 
expression in the HV strains. In this sensitive assay, I also determined that strain 630 was 
significantly lower in tcdA gene expression than strains VPI 10463, K14, BI17, and BI23 
(p≤0.004), while as noted earlier, no toxin protein was detectable during exponential 
phase. 
In contrast, high relative expression of tcdA was seen in stationary phase samples 
(Figure 23 B). Strain VPI 10463 showed significantly higher tcdA expression compared 
to all other strains (p≤0.05), which was consistent with the ELISA results for toxin 
production. The expression of tcdA of all HV strains was, on average, not significantly 
different from all non-HV strains together.  
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Figure 23. A. Transcription of tcdA during exponential phase, relative to transcription of 
the housekeeping gene, rpoA. Means and standard errors of 3 biological replicates are 
shown. B. Transcription of tcdA during stationary phase, relative to transcription of the 
housekeeping gene, rpoA. Means and standard errors of 3 biological replicates are shown. 
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A similar pattern of expression was observed for the tcdB gene in exponential 
phase (Figure 24 A). There was a small but statistically significant (p ≤0.02) 3-fold 
higher expression in the HV strains versus the non-HV strains in exponential phase. 
During stationary phase, strain VPI 10463 exhibited the highest tcdB expression level of 
all strains tested (Figure 24 B), consistent with toxin levels as determined by ELISA.  
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Figure 24. A. Transcription of tcdB during exponential phase, relative to transcription of 
the housekeeping gene, rpoA. Means and standard errors of 3 biological replicates are 
shown. B. Transcription of tcdB during stationary phase, relative to transcription of the 
housekeeping gene, rpoA. Means and standard errors of 3 biological replicates are shown. 
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TcdR is the sigma factor that directs toxin gene expression. If toxin production 
were indeed dysregulated in HV strains, and occurred during exponential growth, then 
the expression of tcdR should be expected to be dysregulated as well, since this protein is 
the positive activator of toxin gene expression. However, consistent with the above 
results, relative expression levels of tcdR were low, and not significantly different 
between HV and non-HV strains during exponential phase (Figure 26 A). 
However, during stationary phase, I observed that tcdR expression was high in all 
strains, and correlated with high toxin levels. High toxin producing strains tended to have 
higher levels of transcript of this sigma factor than low toxin producers (Figure 26 B). 
Expression of tcdR in the HV strains was, on average, 1.2 fold higher than in all non-HV 
strains.  
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Figure 25. A. Transcription of tcdR during exponential phase, relative to transcription of 
the housekeeping gene, rpoA. Means and standard errors of 3 biological replicates are 
shown. B. Transcription of tcdR during stationary phase, relative to transcription of the 
housekeeping gene, rpoA. Means and standard errors of 3 biological replicates are shown. 
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Expression of tcdC occurred in exponential phase, and contrary to previous data 
obtained with strain VPI 10463 [119], this expression increased, rather than decreased, in 
all strains, including VPI 10463 during stationary phase (Figures 27 A and 27 B). 
Although there was evidence of tcdC transcription in the HV strains, it should be noted 
that this expression does not result in a functional protein; thus the relevance of tcdC 
expression in these strains is unclear. Expression of tcdC during exponential phase was 
higher in strain K14 than in the other strains (p≤0.001).  
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Figure 26 A.  Transcription of tcdC during exponential phase, relative to transcription of 
the housekeeping gene, rpoA. Means and standard errors of 3 biological replicates are 
shown. B. Transcription of tcdC during stationary phase, relative to transcription of the 
housekeeping gene, rpoA. Means and standard errors of 3 biological replicates are shown. 
0.00001
0.0001
0.001
0.01
0.1
1
10
630 VPI J9 K14 BI6 BI8 BI17 BI23
R
e
la
ti
v
e
 t
cd
C
e
x
p
re
ss
io
n
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
0.00001
0.0001
0.001
0.01
0.1
1
10
630 VPI J9 K14 BI6 BI8 BI17 BI23
R
e
la
ti
v
e
 t
cd
C
e
x
p
re
ss
io
n
107 
 
 
 
Summary  
Consistent with my hypothesis about the role of TcdC, toxins were undetectable 
during exponential growth, and tcdA, tcdB and tcdR genes showed low, basal levels of 
transcription in both hypervirulent and non-hypervirulent strains. During the stationary 
phase of growth, hypervirulent strains produced robust but not significantly increased 
amounts of toxin as compared to the average of four non-hypervirulent strains Total toxin 
amounts were directly proportional to tcdA, tcdB and tcdR gene expression. Contrary to 
previous work, I found that tcdC expression did not diminish in stationary phase. 
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Sporulation 
Introduction 
Clostridium difficile has several strategies to adapt to nutrient limitation or non-
optimal environmental conditions. In a host environment, the production of toxins 
damages host cells, releasing nutrients for uptake. C. difficile also sporulates in response 
to starvation or the presence of oxygen. Both these stationary phase responses are tightly 
regulated by factors that assess environmental conditions. One of these is the response 
regulator CodY, which represses sporulation and toxin production during exponential 
growth [125]. In Bacillus subtilis, a complex network of two-component systems 
regulates stationary phase phenomena such as competence, antibiotic production, and 
sporulation. These phenomena can be mutally exclusive, as the accumulating of 
nutritional signals activates successive regulatory switches, culminating in the 
commitment to sporulation [260]. 
 In CD, the relationship between toxin production and sporulation is the subject of 
debate. They may be somewhat mutually exclusive, as an inverse relationship was noted 
between toxin yield and spore counts in a survey of toxigenic strains [203]. For example, 
if bacteria sporulate early, there would be less time in which to produce toxin. 
Conversely, an extended time of toxin production in limiting conditions might leave the 
cell vulnerable to death before sporulation is complete.  
The HV strains raise some interesting questions concerning this potential inverse 
relationship between toxin production and sporulation. If HV strains are high toxin 
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producers, then does the previous relationship between toxin and sporulation hold? As 
mentioned earlier, HV strains have spread widely and quickly. Does an increased ability 
to sporulate confer an adaptive advantage that promotes epidemics by HV strains? To 
answer these questions, I determined the course of sporulation over the growth cycle by 
selective treatment and plating of samples taken over the growth cycle. 
HV strains sporulated more efficiently than non-HV strains 
Since the C. difficile spore is the etiologic, transmissible agent, any alteration in 
sporulation efficiency can impact the degree of environmental dissemination. I 
determined the accumulation of spores over the growth cycle, and found that in HV 
strains, spores appeared earlier, and more spores accumulated per total volume of culture 
than non-HV strains. HV strain spore accumulation commenced at 28 hours in BHI broth, 
prior to any non-HV strain (Figure 27 A). At 48 hours, HV strains BI6 and BI8 had 
accumulated significantly more spores than all other strains. HV strains BI17 and BI23 
had accumulated significantly more spores than strains 630, VPI 10463, J9 and K14. 
When calculated as the number of spores formed per total number of vegetative cells at 
the end of exponential growth (efficiency), HV strains also had the greatest efficiency (up 
to 3.55%), as compared with non-HV strains (≤0.66%; not shown).  
Sporulation efficiency evaluated using microscopy also indicated similar trends (Figure 
27 B). The highest numbers of spores were seen in HV strains BI6 and BI17, which were 
not significantly different from each other, but which accumulated significantly more 
spores than the other six strains (p<0.05). 
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Figure 27. A. Spores as heat-resistant colony forming units over 48 hours of growth. 
Means and standard errors of three biological replicates are shown. B. Mean spores 
(defined as all refractile bodies, including sporangia) counted per field by microscopy.
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CHAPTER FOUR 
DISCUSSION 
 
Commensals and Pathogens 
Why do pathogens evolve? Of course, they evolve because the particular 
environment requires them to do so to survive, or a new niche provides an opportunity for 
a particular variation to expand. If pathogenesis is an adaptation, what drives how 
virulent a given pathogen is? If there is a range of pathogenicity, it has been hypothesized 
that it is ecologically most optimal for a pathogen to be moderately virulent, and 
extremes on the continuum are not as successful. Using viruses as an example, it has been 
argued that the Ebola virus is not well-adapted to humans, because it is so virulent it kills 
its host too quickly to spread effectively [261]. When a pathogen makes the jump to a 
new host, there is often a high-attrition evolutionary war in which both host and pathogen 
adapt, with the pathogen eventually becoming less virulent. One example is the 
emergence of the recent highly virulent human pathogen HIV from the more benign 
simian SIV. Recent estimates date the acquisition of SIV by non-human primates at 
32,000 years ago, which is more consistent with the evolution of the virus to a less 
virulent form [262].  
Similarly, among bacteria, there may be situations in which it may be more adaptive 
to be less pathogenic. For example, Vibrio cholerae can exist as a human pathogen or as a 
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non-pathogenic free-living freshwater organism. Disease-causing bacteria promote their 
expansion by transferring pathogenic genes to previously non-pathogenic strains. 
However, improved water sanitation practices can select for the survival of non-
pathogenic strains [263]. 
In contrast to pathogens, gut commensal bacteria lead a domesticated life. In return 
for abundant nutrients, innate immune factors and abundant secretory IgA contain them 
in the gut compartment. However, commensals may have pathogenic capacity if they 
escape and grow elsewhere in the body. For example, Bacteroides fragilis is one of the 
more commonly identified members of the gut biota, but it can cause infections [264]. 
True pathogens such as Shigella are not normal parts of the microbiota. They can evade 
the physical and humoral barriers to invade tissues and cause systemic infections. 
However, asymptomatic carriage can follow infection, which illustrates the fact that a 
robust immune response can turn a pathogen into a temporary commensal. Of course, 
asymptomatic carriage can act to a pathogen’s advantage by promoting spread to new 
hosts. 
The pathogenicity of C. difficile prompts similar questions. Where does CD fall on 
this continuum of commensal to opportunistic pathogen? Humans can carry CD 
asymptomatically. In a survey of hospital patients, being asymptomatically colonized 
with CD actually decreased the likelihood that a patient would exhibit symptomatic 
disease [265]. These asymptomatic carriers most likely have a robust immune response to 
Toxin A [266]. 
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Further, why do some strains contain the PaLoc while others do not? The C. 
difficile genome has many genes acquired through horizontal gene transfer [182], and it 
appears the PaLoc has been acquired more than once, and is not the result of a single 
founding event [267]. Also, it appears that the PaLoc has been lost in non-toxigenic CD 
in multiple independent events, rather than that it was never acquired [200]. Non-
toxigenic strains are certainly successful colonizers of humans. One non-toxigenic strain, 
M3 was the most commonly found non-toxigenic CD strain in a survey of one hospital in 
MN [221]. Strain M3 also sporulates well (Susan Sambol, personal communication), and 
it can out-compete other toxigenic strains in the animal model [221]. It appears that 
pathogenicity is not the only successful path. 
Adaptation of CD to Animal Hosts 
C difficile is well adapted to the animal gut. As an obligate anaerobe, CD limits its 
germination to environments which not only contain nutrients required for growth, but 
specific indicators of the human host, namely bile salts and a lack of oxygen. The 
presence of these features initiates germination and vegetative growth, but not necessarily 
pathogenesis.  
In many viruses, growth and virulence often occur concomitantly. In contrast, in 
bacterial pathogens the signal to express virulence factors does not necessarily come from 
the engagement of a surface receptor. Instead the triggers for the expression of virulence 
factors come from metabolic cues rather than contact. For example, Listeria 
monocytogenes differentiates the human host environment versus the saprophytic 
environment, and the activation of a master regulator of virulence factors, by the 
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availability of carbon sources characteristic of animal cells versus plant cells [268]. The 
mutualist/pathogen Photorhabdus luminescens also switches lifestyles based on cues 
from growth phase and nutrient availability, utilizing a metabolic switch in the TCA 
cycle [269]. Bacterial virulence factors are often not expressed until nutrients are limited. 
In CD, toxins are induced during starvation, which is consistent with the idea of toxin 
production as a nutrient scavenging strategy.  
The mechanism of the action of Toxin B provides evidence of an intimate 
adaptation to animal hosts. First, the acidification of the host endosome allows Toxin B to 
change conformation and insert into the membrane [144]. Second, the presence of a host 
co-factor, inositol hexakisphosphate, induces autocatalytic cleavage and allows the 
enzymatic domain to enter the cytoplasm and glucosylate its targets [149]. This feature is 
unique among bacterial toxins, and suggests that a direct animal interaction has driven the 
adaptation of toxin production. 
We can only speculate about the role of humans as a CD host before the antibiotic 
era. Colonization may have been limited to infants or those with gut related injuries. 
However, it is undeniable that the invention of antibiotics has allowed CD to become 
successful professional pathogen. As mentioned earlier, any antibiotic that disrupts the 
gut microbiota can allow CD to colonize, but antibiotic resistance offers a distinct 
advantage. CD is also well-adapted to the pharmaceutical landscape as it has acquired 
multiple types of antibiotic resistance genes [32, 182, 270-272]. This is true even for non-
toxigenic strains [219]. 
115 
 
 
 Whether CD has adapted to particular species is under investigation. CD affects 
humans, pigs, cows and horses, with varying pathogenicity [273, 274]. In pigs, CDI is not 
fatal, but does cause wasting, in which piglets do not gain weight. Most, but not all, non-
human animal derived CD isolates cluster into a distinct phylogenetic group by micro-
array [200]. A further microarray study indicated that different sets of genes were 
conserved in CD strains from specific host species, which suggests some species 
adaptation [275]. Current studies in the Vedantam lab are testing whether human, porcine 
or bovine strains adhere better to cells in culture from the host organism in which they 
were isolated.  
Adherence of the bacterium to host cells is another feature for which there may be 
a continuum of adaptation. We might assume that it is better to be more adherent, but this 
must be tested empirically. Do commensals adhere more or less than pathogens? 
Certainly, pathogens that invade the body from the gut, or replicate intracellularly, must 
make intimate contact with the host cells. What kind of adherence is adaptive for CD, as 
a non-invasive toxin producer? When I began my work on hypervirulent CD, these were 
the questions I wanted to investigate. 
Adherence Varies Between Strains and Is Multifactorial 
My initial comparisons were between HV strains and other toxigenic CD strains 
that had caused epidemics, to compare the previously most successful CD strains to HV 
strains. While these results indicated that HV strains might be more adherent than other 
strains, my survey of a larger group of strains indicated a wide variety of adherence 
values, with the HV strains averaging slightly below the mean of all strains tested. The 
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HV strains were not homologous as a group in their level of adherence. Other genetic 
groups, such as the J and K group, in which I tested two strains, also indicated variability.  
Considering that it is typical for bacteria to have a whole repertoire of adhesins, 
and that the expression of these adhesins can be regulated, it is not surprising that even 
closely related strains of CD can vary so widely in their adherence. Adherence is a 
multifactorial phenomenon, and does not appear to be even broadly correlated, either 
positively or negatively, with levels of toxin production (at least within the limits of my 
in vitro assay). While the non-toxigenic strains such as M3, M23, and T7 were highly 
adherent, so were several toxigenic strains. 
Contribution of SlpA to Adherence and Colonization 
My antibody and protein interference assays indicated that the surface layer 
protein SlpA is involved in adherence. Most adhesins are typically surface associated 
molecules that have regulated expression. For example, flagella are employed for surface 
contact and then shed when a sessile life style is achieved, such as in a biofilm [276]. One 
example from C. difficile is the adhesin Cwp66, which is down regulated during 
stationary phase, but up-regulated in the presence of certain stressors, such as antibiotics 
[277, 278]. 
SlpA is not a typical adhesin, in that the lattice of the S-layer covers the whole 
cell. As the cell grows, new layers grow and overlap the old in sheets. So increased 
expression of slpA would not provide additional binding epitopes on the surface; the cell 
is already covered with them. So how does SlpA serve as an adhesin? Its stability and 
ubiquity may be advantageous under certain conditions. For example, if other adhesins 
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are down regulated during stationary phase, SlpA is always present to serve as an 
alternate, high avidity adhesin. 
 Microarray studies indicate that slpA expression is increased during stationary 
phase [278]. My cross-interference assays confirmed that adherence inhibition occurred 
when using SLP preparations from non-cognate C. difficile strains. I also found that SlpA 
was secreted into the extracellular millieu. Taken together, these findings hint at another 
function of SlpA. As mentioned earlier, in the animal model of CDI, the colonization of 
one CD strain prevents the subsequent colonization of another. The mechanism for this 
exclusion is not known. However it is likely to be different from the mechanism by which 
the normal gut microbiota exclude CD, since it would be maladaptive to inhibit the 
outgrowth of cognate spores. If it were merely competition for nutrients, one would 
expect to see a more graded outcome of competition, rather than all-or-none exclusion. 
My results suggest that secreted surface proteins could prevent C. difficile 
colonization by competitively excluding bacterial adherence. This idea is supported by 
studies of other mucosally associated bacteria. For example, surface layer extracts from 
Lactobacillus helveticus inhibit the adherence of enterhemorrhagic E. coli O157:H7 to 
epithelial cells (19).  
 
SlpA Subunit Sequence and Function 
I sequenced slpA from eight strains and compared them to the published sequence 
of strain 630. Consistent with previous studies [233, 252], my sequencing results indicate 
that the LMW subunit was more variable, and the HMW subunit was more conserved. 
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Because of the small sample size, the percentages of identity do not dovetail with the four 
clade grouping of CD described in the introduction, except for the HV strains. The four 
HV strains were identical. Members of the other clades, HA1 and A-B+, were no more 
similar to each other than to members of the other clade, which reflects not only my small 
sample size, but also the diversity of these large clades. 
 SlpA, especially the LMW subunit, in addition to being highly variable, is also 
antigenic. This antigenicity has led some to suggest that SlpA could be included in multi-
component vaccine candidates for the prevention of CDI [67, 279, 280]. However, SlpA 
may actually be too variable to provide effective immunity to a broad range of strains. 
This high variability and antigenicity suggest that SlpA may be under positive selection 
for evasion of the host immune response. The hypothesis of positive selection imposed by 
host immune system can be tested examining the ratio of non-synonymous changes (dN) 
to synonymous changes (dS) [281]. Using this analysis, other slpA sequencing projects 
have noted that the HMW peptide is more divergent than the downstream gene, a SecA 
homologue, consistent with positive selection [252]. The LMW peptide sequences are so 
variable that divergence is difficult to assess using a limited number of strains, so similar 
analyses were not been performed in that work [252]. A more recent analysis, using 
whole genome sequencing of thirty CD strains, found evidence of 12 positively selected 
genes, shown in Table # [267]. While the authors admit this may be an underestimate, 
neither SlpA nor any of its surface associated neighbors were in the positively selected 
group [267]. The two-subunit structure of SlpA, with its variable and conserved regions, 
may render such analysis difficult. 
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Table 6. Positively selected core genes in C. difficile. Adapted from He et al, PNAS 2010. 
Gene name refers to systematic identifiers in strain 630. 
Name Annotation 
CD0195 Putative membrane protein 
CD0707 Putative signaling protein 
CD1068 Putative polysaccharide biosynthesis/sporulation protein 
CD1755 Putative ABC transporter, permease protein 
CD1989  Putative membrane protein 
CD2022 Hypothetical protein 
CD2316 Two-component response regulator 
CD2454  Hypothetical protein 
CD2468  Putative exported protein 
CD3094  Putative sigma-54-dependent transcriptional regulator 
CD3248  Putative polysaccharide deacetylase 
CD3558  BirA bifunctional protein 
 
 The LMW subunits of 630 and K14 were only 20% identical, while the HMW 
subunits were nearly 80% identical. While different, my recombinant protein interference 
assays indicate that the LMW subunits from both strains impacted host binding. How is 
this possible? The divergence of the LMW subunit may have multiple constraints: 
changing enough to evade the immune system, while maintaining its function in host 
binding. This may be why one explanation of why it is not positively selected; instead, 
SlpA may be subject to balancing selection. 
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There are multiple described adhesins in CD, and some are variable, some are 
conserved. Cwp66 has also been shown to vary at the amino acid level between strains 
[231], although it is not known how this variation might contribute to colonization. In 
contrast, one other adhesin, the flagellar cap FliD, has a highly conserved sequence, 
which is notable in a highly immunogenic structure. Thus it has been argued that this 
indicates stabilizing selection (i.e., selection against any directional changes) for an 
adhesive function [282]. 
 My recombinant protein experiments suggest that the HMW subunit may not 
contribute not as much to adherence, although further work will be required to confirm 
any significant differnces. This is in contrast to the data of Calabi et al, who found that 
the HMW bound to gastrointestinal tissues, while the LMW did not [232]. That and other 
work had supported the idea of the HMW subunit as the conserved member of the 
complex, and the one responsible for mediating adherence. However, my data are more 
consistent with the crystal structure model of the SlpA molecule, which shows the LMW 
subunit more surface exposed, and the HMW subunit more closely associated with the 
peptidoglycan.  
 Sequence variation may not only affect affinity of SlpA for its target, it may also 
change the nature of the target entirely. In a study using the hamster model, Goulding et 
al found that strains 630 and B1 (a highly toxigenic but non-HV strain) differed in 
localization of adherence in the hamster gut. Strain 630 was found more frequently in the 
crypts, while strain B1 adhered more to the mucosal surface. 
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Considering the multifactorial possibilities, it seems unlikely that the variation in 
SlpA would be responsible for a significant proportion of the variance in adherence. But I 
wanted to test whether highly adherent CD strains had highly adherent SlpA. My 
recombinant protein interference assays showed trends suggesting that both subunits of 
strain 630 had lower IC50 values than both subunits of strain K14. However, strong 
conclusions cnnot be drawn fromthis limited data set. Further work will be required to 
determine if strains which are highly adherent have SlpA molecules, both the LMW and 
the HMW subunits, which are more adherent. 
Summary 
Taken together, the results from the studies presented here indicate that that some 
C. difficile strains have increased adherence to human intestinal epithelial cells that is 
mediated in part by surface-layer protein A (SlpA). The LMW subunit, despite high 
variability, may be more involved than the HMW subunit in mediating adherence of SlpA 
to host cells.  
Pathoadaptation of HV strains 
 Our hypothesis at the beginning of this work was that the HV phenotype was due 
to more than a simple disruption in toxin regulation. The wealth of genomic data that has 
accumulated in the past several years supports the idea of the micro-evolution of HV 
strains.  
 A change in hosts or a shift in virulence usually requires a pathogen to acquire 
new genes, either by horizontal gene transfer or by mutation. Surveys of HV strains 
indicate a gain of 234 additional genes as compared to strain 630 [283]. These genes not 
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only include typical horizontally transmitted genes such as antibiotic resistance and 
phage elements, but also include new regulators and a two-component system. One of the 
features of pathoadaptation is the development of new regulatory controls for new or 
pathoadapted genes. 
Another feature of pathoadaptation is the loss of genes that may interfere with 
new function. These are termed “antivirulence genes” [284]. HV CD has lost 13 genes 
[200](Table 7), which include a membrane associated gene, and one surface anchored 
gene, but again, do not include genes from the cluster in which slpA resides. slpA itself 
could not be lost, as it is essential [Julian Rood, personal communication]. The 
relationship between genes lost and virulence may not be obvious. To demonstrate that a 
particular lost gene is an antivirulence gene, experiments would have to be conducted to 
re-introduce the gene and then demonstrate a loss in virulence. These genes would be 
interesting to investigate in the future, especially in the animal model of CDI.  
 
TABLE 7. Gene deletions specific to the Hypervirulent (HY) clade. Adapted from 
Stabler 06. 
Loci  Deletion(s)/divergent genes. 
CD0630-CD0719 Methenyltetrahydrofolate cyclohydrolase  
CD0630-CD0720 Putative FolD bifunctional protein (includes 
methylenetetrahydrofolate dehydrogenase and 
methenyltetrahydrofolate cyclohydrolase)  
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CD0630-CD0721 Conserved hypothetical protein  
CD0630-CD0722 Putative methylenetetrahydrofolate reductase  
CD0630-CD0723 Putative carbon monoxide dehydrogenase/ acetyl 
coenzyme A synthase complex, dihydrolipoyl 
dehydrogenase subunit 
CD0630-CD0724 Putative carbon monoxide dehydrogenase/ acetyl 
coenzyme A synthase complex, nickel-inserting subunit 
CD0630-CD1744 Two-component sensor histidine kinase  
CD0630-CD1745 Hypothetical protein  
CD0630-CD2013 TetR family transcriptional regulator  
CD0630-CD2599 Putative general stress protein  
CD0630-CD3140 Putative membrane protein  
CD0630-CD3144 Putative transcriptional regulator  
CD0630-CD3145 Putative serine-aspartate-rich surfaceanchored 
fibrinogen binding protein 
 
 
Toxin production in HV strains of C. difficile 
In the past decade, there has been great interest in elucidating the molecular 
mechanisms contributing to the hypervirulent phenotype, particularly those involved in 
toxin production. My data indicate that in C. difficile, the four HV strains tested do not 
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make more toxin than all non-HV C. difficile strains tested, and my data also clarify the 
timing of the onset of toxin production. My evaluation of sporulation found a significant 
difference in the production of infectious particles by HV strains, the magnitude of which 
exceeds any difference in the production of toxins. 
In this work, I have shown that HV C. difficile strains do not make the toxins TcdA 
or TcdB during exponential growth. However, HV strains do produce toxin amounts 
comparable to, or exceeding, those of other strains during stationary phase. Even this 
small sample of non-HV strains exhibited a wide range of toxin production. This variance 
illustrates the importance of the choice of comparator strains when making 
generalizations about the HV phenotype. Previous studies [194] may have 
underestimated the significance of these variances in toxin production, leading to 
misattributions about the potential mechanisms of hypervirulence. If there have been 
other high toxin producers, but that have not become epidemic, then there must be other 
hypervirulence mechanisms. For example, Strain VPI10463, or other isolates from its 
genetic REA group (Z) are not often found in surveys of patient isolates (Dale Gerding, 
unpublished data). 
I conducted my experiments in BHI medium, which contains glucose, a known 
repressor of toxin gene expression. The kinetics of the onset of toxin gene production 
might vary in different media. For example, when CD is grown in media which lacks 
glucose, toxin production does appear earlier [128]. Unfortunately, direct comparison 
with the medium used in the study by Warny et al is not possible because they used a 
proprietary medium. However, the point is not the exact time of onset, but the difference 
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between HV and non-HV strains relative to the tcdC deletion. As discussed further in 
later sections, this difference should not affect the HV strains differently, because the 
nutritional regulators of toxin production, such as CodY do not differ between HV and 
non HV strains   
The negative regulator TcdC has been at the center of the debate about toxin 
production in HV strains. A previous study of the transcription of PaLoc genes in strain 
VPI 10463 indicated that tcdC was highly expressed during exponential phase, and that 
this expression diminished as growth slowed in stationary phase [119]. These data, along 
with those indicating that TcdC prevents TcdR from complexing with RNA polymerase, 
led to the model in which TcdC acts as a negative regulator of toxin gene expression in 
exponential phase [124]. Most HV clade C. difficile isolates have a frame-shift mutation 
in tcdC which would result in a truncated 65 amino acid protein [208]. Warny et al 
hypothesized that the lack of a functional TcdC results in transcription of the toxin genes 
and production of toxin protein during exponential growth [194]. However, my results 
clearly demonstrate that there is no TcdA/B protein detectable in exponential phase, and 
that tcdA is no more highly expressed in HV strains than non-HV strains in exponential 
phase, and tcdB expression is only slightly higher in HV strains.  
These data are consistent with the absolute requirement of TcdR for toxin gene 
expression, and the strong repression of tcdR (observed by us and others) in exponential 
phase [119, 122, 125]. Thus, the absence of TcdC is likely not sufficient to permit toxin 
production during exponential growth, and underscores the critical requirement of TcdR 
for TcdA/B expression.  
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The prevailing model of TcdC as a negative regulator of toxin gene expression 
describes TcdC protein diminishing (by an unknown regulatory mechanism) in stationary 
phase. However, I observed relatively high transcription of tcdC in stationary phase. This 
finding is consistent with recently published data. In particular, while examining the role 
of CodY (a global regulator of gene expression in gram positive bacteria) in toxin gene 
repression, Dineen and colleagues found that in strain 630, tcdC was expressed during 
both exponential and stationary phase [125]. Karlsson et al also demonstrated that tcdC 
expression increases in stationary phase, and that this expression was suppressed by 
nutrient supplementation similar to that seen for the toxin genes [131].  
I thus hypothesize that TcdC, while not required for exponential phase tcdA/B 
repression, may exert a modulatory effect on toxin production. The lack of this modulator 
in HV strains may be one reason they show relatively high toxin production in stationary 
phase. I hypothesize that in exponential phase, small amounts of TcdC may inhibit any 
rare upstream read-through transcription, which may explain the slight but significant 
increase in exponential phase tcdB expression in the HV strains.  
However, there are likely multiple influences on the quantity of toxins produced 
by various strains. TcdC protein levels may be one factor; the affinity of TcdC for its 
targets may be another. For example, strains 630 and VPI 10463 both have functional 
TcdC proteins, but exhibit vastly different toxin production.  
My transcriptional studies showed significantly different basal levels of 
transcription of the four PaLoc genes for different strains. We hypothesized that this may 
be due to differences in upstream elements. To begin to explain some of these trends in 
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gene expression, my co-authors in the publication of this work, Michael Mallozzi and 
Bryan Roxas, examined genetic differences that might produce variations in transcription 
and translation of toxin genes and proteins, respectively. They performed an alignment of 
the PaLoc DNA sequences of two closely related strains, 630 and VPI 10463, which 
exhibited the lowest and highest levels of transcription of toxin and toxin regulating 
genes, respectively, across all growth phases. The sequence differences in these strains 
are likely to be responsible for the differences in the amount of toxin produced since they 
share a common ancestor (as they both fall within the HA1 clade [200]). Briefly, Bryan 
and Michael aligned the sequences using the ClustalW algorithm [285] in the BioEdit 
program [286], predicted and analyzed existing promoters [119], predicted transcriptional 
terminators [287], and annotated ribosomal binding sequences manually based on the E. 
coli consensus sequence. The free energy of RNA secondary structures was estimated 
using the RNAfold webserver [http://rna.tbi.univie.ac.at/].  
This analysis discovered several interesting differences in the sequences of these 
strains relevant to PaLoc expression. First, the negative regulator (tcdC) of VPI 10463 
contains a mutation that changes Aspartic Acid 7 of the TcdC protein to Glutamic Acid, 
which may change its affinity for TcdR or RNA polymerase (potentially lessening its 
negative-regulating capacity). Second, while the promoter sequences of all of the PaLoc 
toxin and toxin regulators are identical, the Ribosomal Binding site (Shine Dalgarno 
sequence) of the tcdR gene in VPI 10463 contains a single nucleotide difference as 
compared to strain 630, which may increase translation of the tcdR transcript.  
Further, two other genetic variations might lead to increased read-through transcription of 
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the tcdB and tcdR genes from upstream promoters (Figure 28). For tcdR, the predicted 
transcriptional terminator for cdu1 (the gene upstream of tcdR) lies within the coding 
sequence of tcdR. Therefore, if the tcdR RBS mutation in VPI 10463 leads to increased 
translation, this could also interfere with the transcriptional termination of the cdu1 gene, 
leading to read-through transcription of tcdR (from the cdu1 promoter), which would 
increase the amount of tcdR transcript in turn allowing for increased transcription of the 
toxin genes. For tcdB, the secondary structure of the RNA encoded by the tcdR and tcdB 
intergenic region has a lower minimum free energy in strain 630 (24.71 kcal/mol) than in 
VPI10463 (-10.92 kcal/mol). This suggests that there may be more read-through 
transcription from the tcdR promoter in strain VPI 10463 than in strain 630, which may 
increase the level of the tcdB transcript in VPI 10463. Determining whether these 
differences are responsible for expression levels cannot be determined from strain or 
sequence comparisons alone, and will require transcriptional studies. 
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Figure 28. Schematic of the C. difficile PaLoc region. Coding regions and predicted 
regulatory elements are depicted. The cdu1 gene has three predicted Rho-independent 
terminators (indicated by hairpins). The formation of any given hairpin usually 
prevents the formation of others downstream. Further, if ter2 forms, transcription 
from ptcdR would be blocked. “ter”, terminator; “p”, promoter; RBS, ribosome 
binding site. Not to scale. 
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Toxin production and sporulation are both responses to nutrient limitation, 
and the relationship between them is a subject of debate. One survey of toxigenic C. 
difficile strains indicated an inverse relationship between toxin yield and spore counts 
[203], suggesting that if bacteria sporulate early in stationary phase, there is less time 
in which to produce toxin. However, an extended time of toxin production under 
nutrient-limited conditions may result in bacterial death before sporulation is 
completed. For example, strain VPI 10463, a known high toxin producer, sporulates 
very poorly [203]. Other studies, however, indicate that mutants of stationary phase 
regulator Spo0A and its associated sensor kinase are impaired not only in sporulation 
but also in toxin production [177]. Further research is thus required to elucidate the 
links between the two systems, and in particular, the role of the tcdC mutation in HV 
strains. One might speculate that TcdC may also disrupt sporulation-associated sigma 
factors or other ECF sigma factors involved in stationary phase phenomena that may 
impact survival [116, 288].  
The data clearly demonstrate that the four strains in the hypervirulent clade of 
C. difficile that I tested not only sporulate with greater efficiency than other strains, 
but also produce robust amounts of toxin. These data are consistent with another 
study of different hypervirulent isolates [213]. HV strains also produce toxin B with 
different intoxicating potential [202]. While the correlation between in vitro toxin 
production and clinical outcomes is not consistent [203], it is possible that the altered 
toxin B phenotype may influence disease severity. Enhanced sporulation may 
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increase the likelihood of disseminating infectious particles into the environment, 
acting synergistically with toxin to give an adaptive advantage for hypervirulent C. 
difficile in terms of pathogenesis.  
Summary 
Most likely, a synergistic confluence of multiple factors has allowed the C. 
difficile hypervirulent phenotype to emerge. Human factors such as the increased use 
of antimicrobials in the hospital and community settings as well as inability to control 
environmental contamination have undoubtedly contributed to CDI outbreaks. 
Bacterial factors that have been described include genetic alterations resulting in 
fluoroquinolone resistance, Toxin B enzymatic variation, high toxin production, and 
increased sporulation. However, my data and that of others indicate that there is much 
more to discover, about hypervirulent C. difficile and about C. difficile pathogenesis 
in general. 
Future Directions  
The variability of the LMW subunit raises interesting questions about the 
relationship of structure, function and selection. It would be interesting to see if the 
LMW subunit could evolve in a way that conserves structure and function, but also 
shifts to avoid the host immune system. Now that there is a crystal structure of the 
LMW subunit from one strain it would be illuminating to thread other sequences over 
this structure and assess how well they match, if at all. Extremely diverse sequences 
can produce very similar structures, one example is the structural similarity of 
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eukaryotic actin and the bacterial proteins ParM and MreB [289]. However, it is 
unknown if such adaptations could evolve on a relatively short time scale. 
To further investigate the pathoadaptation of HV strains in terms of their 
interaction with the host, some of the genes that have been lost in the HV clade could 
be re-introduced, to test if they are indeed anti-virulence genes. These genes could be 
re-introduced either on a plasmid or on a transposon, and then any differences could 
be noted in adherence, toxin production, sporulation, or virulence in the animal 
model. 
To further investigate the regulation of toxins, it would be informative to re-
introduce a functional copy of tcdC, either on a plasmid or on a transposon. If the re-
introduced gene was placed under the control of an inducible promoter, then my 
hypothesis that TcdC acts as a modulator could be tested. If the hypothesized 
relationship is correct, then one would expect that toxin transcription and protein 
production would be inversely correlated with the amount of TcdC.  
Using the same approach, one could also test for effects on sporulation. If a 
relationship between TcdC and sporulation efficiency was found, then an 
investigation of other potential ECF sigma factor targets in the CD genome could 
begin. 
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